Details of the Drug Combinations

General Information of This Drug (ID: DM7C8YV)

Drug Name
Plicamycin   DM7C8YV
Synonyms A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01
Indication
Disease Entry ICD 11 Status REF
Hypercalcaemia 5B91.0 Approved [1]
Testicular cancer 2C80 Approved [1]
Solid tumour/cancer 2A00-2F9Z Withdrawn from market [2]
Lung cancer 2C25.0 Investigative [3]
Ovarian cancer 2C73 Investigative [3]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1370 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
10-hydroxycamptothecin + Plicamycin DCWHJT9 10-hydroxycamptothecin Astrocytoma (Cell Line: U251) [4]
10-hydroxycamptothecin + Plicamycin DCZ8IXA 10-hydroxycamptothecin Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
10-hydroxycamptothecin + Plicamycin DCFIAN7 10-hydroxycamptothecin Glioma (Cell Line: SF-295) [4]
10-hydroxycamptothecin + Plicamycin DCJ92R4 10-hydroxycamptothecin Glioma (Cell Line: SF-539) [4]
10-hydroxycamptothecin + Plicamycin DCXNNX5 10-hydroxycamptothecin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
10-hydroxycamptothecin + Plicamycin DC6WNSL 10-hydroxycamptothecin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
10-hydroxycamptothecin + Plicamycin DCQKVOF 10-hydroxycamptothecin Adenocarcinoma (Cell Line: DU-145) [6]
10-hydroxycamptothecin + Plicamycin DCFCX88 10-hydroxycamptothecin Large cell lung carcinoma (Cell Line: NCI-H460) [6]
ABIRATERONE + Plicamycin DCM3SEG ABIRATERONE Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
ABIRATERONE + Plicamycin DCLRX99 ABIRATERONE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
ABIRATERONE + Plicamycin DCSSNM4 ABIRATERONE Astrocytoma (Cell Line: U251) [4]
ABIRATERONE + Plicamycin DCW9DMG ABIRATERONE Astrocytoma (Cell Line: SNB-19) [4]
ABIRATERONE + Plicamycin DCG14QT ABIRATERONE Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
ABIRATERONE + Plicamycin DCY8SRU ABIRATERONE Chronic myelogenous leukemia (Cell Line: K-562) [4]
ABIRATERONE + Plicamycin DCHM91D ABIRATERONE Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
ABIRATERONE + Plicamycin DCM9G39 ABIRATERONE Clear cell renal cell carcinoma (Cell Line: A498) [4]
ABIRATERONE + Plicamycin DCX3VDW ABIRATERONE Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
ABIRATERONE + Plicamycin DC15MP5 ABIRATERONE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
ABIRATERONE + Plicamycin DCK9BT7 ABIRATERONE Glioblastoma (Cell Line: SNB-75) [4]
ABIRATERONE + Plicamycin DCWHA60 ABIRATERONE Glioma (Cell Line: SF-295) [4]
ABIRATERONE + Plicamycin DCUFL1V ABIRATERONE Glioma (Cell Line: SF-539) [4]
ABIRATERONE + Plicamycin DCC78EE ABIRATERONE Papillary renal cell carcinoma (Cell Line: ACHN) [4]
ABIRATERONE + Plicamycin DCEWB22 ABIRATERONE Plasma cell myeloma (Cell Line: RPMI-8226) [4]
ABIRATERONE + Plicamycin DC4YK5L ABIRATERONE Renal cell carcinoma (Cell Line: UO-31) [4]
ABIRATERONE + Plicamycin DCUYOOI ABIRATERONE Renal cell carcinoma (Cell Line: SN12C) [4]
ABIRATERONE + Plicamycin DC3A52F ABIRATERONE Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
ABIRATERONE + Plicamycin DCC0NXQ ABIRATERONE Carcinoma (Cell Line: MCF7) [5]
ABIRATERONE + Plicamycin DC20TBS ABIRATERONE Colon adenocarcinoma (Cell Line: COLO 205) [5]
ABIRATERONE + Plicamycin DCJIWN6 ABIRATERONE Colon carcinoma (Cell Line: KM12) [5]
ABIRATERONE + Plicamycin DCBCYQ1 ABIRATERONE Invasive ductal carcinoma (Cell Line: BT-549) [5]
ABIRATERONE + Plicamycin DCKC3D6 ABIRATERONE Invasive ductal carcinoma (Cell Line: T-47D) [5]
ABIRATERONE + Plicamycin DCK3LOJ ABIRATERONE Invasive ductal carcinoma (Cell Line: HS 578T) [5]
ABIRATERONE + Plicamycin DCP4C65 ABIRATERONE Adenocarcinoma (Cell Line: DU-145) [6]
ABIRATERONE + Plicamycin DC08NY5 ABIRATERONE Adenocarcinoma (Cell Line: OVCAR3) [6]
ABIRATERONE + Plicamycin DCDKMVK ABIRATERONE Adenocarcinoma (Cell Line: HCT116) [6]
ABIRATERONE + Plicamycin DCKR6JF ABIRATERONE Amelanotic melanoma (Cell Line: M14) [6]
ABIRATERONE + Plicamycin DCI5JL6 ABIRATERONE Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
ABIRATERONE + Plicamycin DCXSE44 ABIRATERONE Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
ABIRATERONE + Plicamycin DC8I3XG ABIRATERONE Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
ABIRATERONE + Plicamycin DCJ2GEH ABIRATERONE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
ABIRATERONE + Plicamycin DC0TMU8 ABIRATERONE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
ABIRATERONE + Plicamycin DCNIN8Z ABIRATERONE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
ABIRATERONE + Plicamycin DC4ID0K ABIRATERONE Large cell lung carcinoma (Cell Line: NCI-H460) [6]
ABIRATERONE + Plicamycin DCYA9D8 ABIRATERONE Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
ABIRATERONE + Plicamycin DC2QCZE ABIRATERONE Lung adenocarcinoma (Cell Line: NCI-H522) [6]
ABIRATERONE + Plicamycin DCO7KCZ ABIRATERONE Malignant melanoma (Cell Line: UACC62) [6]
ABIRATERONE + Plicamycin DCXANDV ABIRATERONE Malignant melanoma (Cell Line: LOX IMVI) [6]
ABIRATERONE + Plicamycin DCO8MWI ABIRATERONE Melanoma (Cell Line: UACC-257) [6]
ABIRATERONE + Plicamycin DCTAERX ABIRATERONE Melanoma (Cell Line: SK-MEL-2) [6]
ABIRATERONE + Plicamycin DC2TZ3Q ABIRATERONE Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
ABIRATERONE + Plicamycin DCOORA0 ABIRATERONE Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
ABIRATERONE + Plicamycin DC088NU ABIRATERONE Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Amonafide + Plicamycin DCSX58R Amonafide Adenocarcinoma (Cell Line: DU-145) [4]
Amonafide + Plicamycin DCQ96Q3 Amonafide Adenocarcinoma (Cell Line: NCIH23) [4]
Amonafide + Plicamycin DCPSYXB Amonafide Adenocarcinoma (Cell Line: HCT116) [4]
Amonafide + Plicamycin DCUZLKL Amonafide Adenocarcinoma (Cell Line: HCC-2998) [4]
Amonafide + Plicamycin DCW570H Amonafide Adenocarcinoma (Cell Line: HCT-15) [4]
Amonafide + Plicamycin DCIQJWI Amonafide Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Amonafide + Plicamycin DCGMJVI Amonafide Astrocytoma (Cell Line: U251) [4]
Amonafide + Plicamycin DCE0OKI Amonafide Chronic myelogenous leukemia (Cell Line: K-562) [4]
Amonafide + Plicamycin DC28KVR Amonafide Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Amonafide + Plicamycin DCSOCE0 Amonafide Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Amonafide + Plicamycin DCBL8S9 Amonafide Glioma (Cell Line: SF-539) [4]
Amonafide + Plicamycin DC46TU2 Amonafide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Amonafide + Plicamycin DC7OLNW Amonafide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Amonafide + Plicamycin DCQUAIG Amonafide Lung adenocarcinoma (Cell Line: HOP-62) [4]
Amonafide + Plicamycin DCP5JW3 Amonafide Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Amonafide + Plicamycin DCIYBII Amonafide Melanoma (Cell Line: SK-MEL-2) [4]
Amonafide + Plicamycin DC8FUGO Amonafide Melanoma (Cell Line: UACC-257) [4]
Amonafide + Plicamycin DCA17FS Amonafide Melanoma (Cell Line: MALME-3M) [4]
Amonafide + Plicamycin DC1QCII Amonafide Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Amonafide + Plicamycin DCENVZI Amonafide Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Amonafide + Plicamycin DCG1MZE Amonafide Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Amonafide + Plicamycin DCAXL1L Amonafide Renal cell carcinoma (Cell Line: SN12C) [4]
Amonafide + Plicamycin DCM04C8 Amonafide Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Amonafide + Plicamycin DCHU68A Amonafide Carcinoma (Cell Line: RXF 393) [5]
Amonafide + Plicamycin DCYNTZ4 Amonafide Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Amonafide + Plicamycin DCMONJU Amonafide Invasive ductal carcinoma (Cell Line: BT-549) [5]
Anastrozole + Plicamycin DCYE4A6 Anastrozole Adenocarcinoma (Cell Line: DU-145) [4]
Anastrozole + Plicamycin DCYXCKT Anastrozole Adenocarcinoma (Cell Line: A549) [4]
Anastrozole + Plicamycin DCIYDZ7 Anastrozole Adenocarcinoma (Cell Line: HT29) [4]
Anastrozole + Plicamycin DCUXZEP Anastrozole Adenocarcinoma (Cell Line: HCC-2998) [4]
Anastrozole + Plicamycin DC90XQF Anastrozole Adenocarcinoma (Cell Line: SW-620) [4]
Anastrozole + Plicamycin DCYY65A Anastrozole Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Anastrozole + Plicamycin DCZ5850 Anastrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Anastrozole + Plicamycin DCGG84H Anastrozole Amelanotic melanoma (Cell Line: M14) [4]
Anastrozole + Plicamycin DCUUUNL Anastrozole Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Anastrozole + Plicamycin DCQSU79 Anastrozole Chronic myelogenous leukemia (Cell Line: K-562) [4]
Anastrozole + Plicamycin DCH73NY Anastrozole Clear cell renal cell carcinoma (Cell Line: A498) [4]
Anastrozole + Plicamycin DCROOSX Anastrozole Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Anastrozole + Plicamycin DCX2QXA Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Anastrozole + Plicamycin DC85V8S Anastrozole Glioblastoma (Cell Line: SNB-75) [4]
Anastrozole + Plicamycin DCF7GQ8 Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Anastrozole + Plicamycin DCVNK5E Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Anastrozole + Plicamycin DCNNX8T Anastrozole Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Anastrozole + Plicamycin DCLLGQC Anastrozole Lung adenocarcinoma (Cell Line: HOP-62) [4]
Anastrozole + Plicamycin DC3PUDI Anastrozole Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Anastrozole + Plicamycin DCKOAP8 Anastrozole Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Anastrozole + Plicamycin DCGXC2H Anastrozole Malignant melanoma (Cell Line: LOX IMVI) [4]
Anastrozole + Plicamycin DCD8ZMI Anastrozole Melanoma (Cell Line: MALME-3M) [4]
Anastrozole + Plicamycin DCD1H8M Anastrozole Melanoma (Cell Line: SK-MEL-2) [4]
Anastrozole + Plicamycin DCM3WX3 Anastrozole Melanoma (Cell Line: UACC-257) [4]
Anastrozole + Plicamycin DCOI9KK Anastrozole Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Anastrozole + Plicamycin DC0S7IC Anastrozole Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Anastrozole + Plicamycin DC3UO3N Anastrozole Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Anastrozole + Plicamycin DCJNKPH Anastrozole Prostate carcinoma (Cell Line: PC-3) [4]
Anastrozole + Plicamycin DC0Q76N Anastrozole Renal cell carcinoma (Cell Line: UO-31) [4]
Anastrozole + Plicamycin DC0L9MR Anastrozole Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Anastrozole + Plicamycin DC2PVBM Anastrozole Carcinoma (Cell Line: RXF 393) [5]
Anastrozole + Plicamycin DC6HWDC Anastrozole Carcinoma (Cell Line: MCF7) [5]
Anastrozole + Plicamycin DC2OUMY Anastrozole Colon adenocarcinoma (Cell Line: COLO 205) [5]
Anastrozole + Plicamycin DCKXCM0 Anastrozole Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Anastrozole + Plicamycin DCK29HU Anastrozole Invasive ductal carcinoma (Cell Line: BT-549) [5]
Arfolitixorin + Plicamycin DCNUH3W Arfolitixorin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Arfolitixorin + Plicamycin DCHQNJA Arfolitixorin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Arfolitixorin + Plicamycin DCAX9WE Arfolitixorin Astrocytoma (Cell Line: U251) [4]
Arfolitixorin + Plicamycin DCJIOHM Arfolitixorin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Arfolitixorin + Plicamycin DCXGX2G Arfolitixorin Clear cell renal cell carcinoma (Cell Line: A498) [4]
Arfolitixorin + Plicamycin DCE48U2 Arfolitixorin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Arfolitixorin + Plicamycin DCU3RMA Arfolitixorin Glioblastoma (Cell Line: SNB-75) [4]
Arfolitixorin + Plicamycin DC0BYLO Arfolitixorin Glioma (Cell Line: SF-268) [4]
Arfolitixorin + Plicamycin DCBTP00 Arfolitixorin Glioma (Cell Line: SF-539) [4]
Arfolitixorin + Plicamycin DCPNN7J Arfolitixorin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Arfolitixorin + Plicamycin DCLVOLC Arfolitixorin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Arfolitixorin + Plicamycin DCLR5YE Arfolitixorin Carcinoma (Cell Line: RXF 393) [5]
Arfolitixorin + Plicamycin DC114D2 Arfolitixorin Colon carcinoma (Cell Line: KM12) [5]
Arfolitixorin + Plicamycin DC9HH1T Arfolitixorin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Arfolitixorin + Plicamycin DCQ0CNF Arfolitixorin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Arfolitixorin + Plicamycin DC9CFYG Arfolitixorin Adenocarcinoma (Cell Line: OVCAR3) [6]
Arfolitixorin + Plicamycin DCCUG75 Arfolitixorin Adenocarcinoma (Cell Line: A549) [6]
Arfolitixorin + Plicamycin DCGN1ZC Arfolitixorin Adenocarcinoma (Cell Line: HCT116) [6]
Arfolitixorin + Plicamycin DCPVDE6 Arfolitixorin Adenocarcinoma (Cell Line: HCC-2998) [6]
Arfolitixorin + Plicamycin DCW0WOI Arfolitixorin Adenocarcinoma (Cell Line: HT29) [6]
Arfolitixorin + Plicamycin DCVIR4L Arfolitixorin Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Arfolitixorin + Plicamycin DCD67ZE Arfolitixorin Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Arfolitixorin + Plicamycin DC2CMWL Arfolitixorin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Arfolitixorin + Plicamycin DCXY2YC Arfolitixorin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Arfolitixorin + Plicamycin DCVHNT7 Arfolitixorin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Arfolitixorin + Plicamycin DCKVOC5 Arfolitixorin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Arfolitixorin + Plicamycin DCO9KER Arfolitixorin Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Arfolitixorin + Plicamycin DCZ136F Arfolitixorin Lung adenocarcinoma (Cell Line: HOP-62) [6]
Arfolitixorin + Plicamycin DCJOF1H Arfolitixorin Lung adenocarcinoma (Cell Line: EKVX) [6]
Arfolitixorin + Plicamycin DCOMOI5 Arfolitixorin Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Arfolitixorin + Plicamycin DC5FKCX Arfolitixorin Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Arfolitixorin + Plicamycin DC1WPAR Arfolitixorin Malignant melanoma (Cell Line: LOX IMVI) [6]
Arfolitixorin + Plicamycin DC9EYB0 Arfolitixorin Malignant melanoma (Cell Line: UACC62) [6]
Arfolitixorin + Plicamycin DCSEYSD Arfolitixorin Melanoma (Cell Line: MALME-3M) [6]
Arfolitixorin + Plicamycin DC8GC5Q Arfolitixorin Melanoma (Cell Line: UACC-257) [6]
Arfolitixorin + Plicamycin DC893YD Arfolitixorin Melanoma (Cell Line: SK-MEL-2) [6]
Arfolitixorin + Plicamycin DCC5SVQ Arfolitixorin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Arfolitixorin + Plicamycin DCJ5WHD Arfolitixorin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Arfolitixorin + Plicamycin DCN8VSD Arfolitixorin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Arfolitixorin + Plicamycin DCUAZVC Arfolitixorin Prostate carcinoma (Cell Line: PC-3) [6]
Azacitidine + Plicamycin DCEAWJK Azacitidine Chronic myelogenous leukemia (Cell Line: K-562) [4]
BIO-300 + Plicamycin DC8GI8Q BIO-300 Anaplastic large cell lymphoma (Cell Line: SR) [4]
BIO-300 + Plicamycin DCIJ2JR BIO-300 Chronic myelogenous leukemia (Cell Line: K-562) [4]
BIO-300 + Plicamycin DC00E21 BIO-300 Clear cell renal cell carcinoma (Cell Line: A498) [4]
BIO-300 + Plicamycin DCN032M BIO-300 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
BIO-300 + Plicamycin DCITZLE BIO-300 Glioma (Cell Line: SF-539) [4]
BIO-300 + Plicamycin DC2K4L4 BIO-300 Papillary renal cell carcinoma (Cell Line: ACHN) [4]
BIO-300 + Plicamycin DCIA5DZ BIO-300 Renal cell carcinoma (Cell Line: SN12C) [4]
BIO-300 + Plicamycin DCQXREG BIO-300 Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
BIO-300 + Plicamycin DCFDP2A BIO-300 Carcinoma (Cell Line: RXF 393) [5]
BIO-300 + Plicamycin DCJK9SP BIO-300 Invasive ductal carcinoma (Cell Line: BT-549) [5]
BIO-300 + Plicamycin DCAFHKK BIO-300 Invasive ductal carcinoma (Cell Line: T-47D) [5]
BIO-300 + Plicamycin DCBXG01 BIO-300 Invasive ductal carcinoma (Cell Line: HS 578T) [5]
BIO-300 + Plicamycin DCXU6PL BIO-300 Adenocarcinoma (Cell Line: OVCAR3) [6]
BIO-300 + Plicamycin DCZSMOV BIO-300 Adenocarcinoma (Cell Line: NCIH23) [6]
BIO-300 + Plicamycin DC40WK2 BIO-300 Adenocarcinoma (Cell Line: HCC-2998) [6]
BIO-300 + Plicamycin DCRR8LE BIO-300 Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
BIO-300 + Plicamycin DCHC6KU BIO-300 Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
BIO-300 + Plicamycin DCZ79WG BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
BIO-300 + Plicamycin DCCHU7S BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
BIO-300 + Plicamycin DCCSPKE BIO-300 Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
BIO-300 + Plicamycin DC0MTIG BIO-300 Lung adenocarcinoma (Cell Line: NCI-H522) [6]
BIO-300 + Plicamycin DC08JHV BIO-300 Malignant melanoma (Cell Line: UACC62) [6]
BIO-300 + Plicamycin DCO83MT BIO-300 Melanoma (Cell Line: MALME-3M) [6]
BIO-300 + Plicamycin DCC292B BIO-300 Melanoma (Cell Line: UACC-257) [6]
BIO-300 + Plicamycin DCD4EFB BIO-300 Melanoma (Cell Line: SK-MEL-2) [6]
BIO-300 + Plicamycin DC0PY6R BIO-300 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
BIO-300 + Plicamycin DCHWEXJ BIO-300 Prostate carcinoma (Cell Line: PC-3) [6]
Bleomycin + Plicamycin DCRMF3U Bleomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Bleomycin + Plicamycin DCO9KSY Bleomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Bleomycin + Plicamycin DC681BC Bleomycin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Bleomycin + Plicamycin DC1ZE0M Bleomycin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Bleomycin + Plicamycin DCMVX8Y Bleomycin Clear cell renal cell carcinoma (Cell Line: A498) [4]
Bleomycin + Plicamycin DCK9A4K Bleomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Bleomycin + Plicamycin DC8HR79 Bleomycin Glioma (Cell Line: SF-539) [4]
Bleomycin + Plicamycin DCZH4IP Bleomycin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Bleomycin + Plicamycin DCPEC90 Bleomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Bleomycin + Plicamycin DCN4DUD Bleomycin Carcinoma (Cell Line: RXF 393) [5]
Bleomycin + Plicamycin DC1Y5D5 Bleomycin Carcinoma (Cell Line: MCF7) [5]
Bleomycin + Plicamycin DC0GGQ5 Bleomycin Colon adenocarcinoma (Cell Line: COLO 205) [5]
Bleomycin + Plicamycin DCOCFEY Bleomycin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Bleomycin + Plicamycin DCOTLNI Bleomycin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Bleomycin + Plicamycin DC2JPQA Bleomycin Invasive ductal carcinoma (Cell Line: T-47D) [5]
Bleomycin + Plicamycin DC8LIP4 Bleomycin Adenocarcinoma (Cell Line: SW-620) [6]
Bleomycin + Plicamycin DC9G5NU Bleomycin Adenocarcinoma (Cell Line: HCT116) [6]
Bleomycin + Plicamycin DCOFS9Q Bleomycin Adenocarcinoma (Cell Line: HCC-2998) [6]
Bleomycin + Plicamycin DCIVN4X Bleomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Bleomycin + Plicamycin DC9DADZ Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Bleomycin + Plicamycin DC40M17 Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Bleomycin + Plicamycin DCDCHY2 Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Bleomycin + Plicamycin DC4P0Z5 Bleomycin Hodgkin lymphoma (Cell Line: L-1236) [6]
Bleomycin + Plicamycin DCZHLLY Bleomycin Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Bleomycin + Plicamycin DCNFVN7 Bleomycin Lung adenocarcinoma (Cell Line: HOP-62) [6]
Bleomycin + Plicamycin DCVHZJL Bleomycin Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Bleomycin + Plicamycin DCCLQNA Bleomycin Melanoma (Cell Line: SK-MEL-2) [6]
Bleomycin + Plicamycin DC70QHB Bleomycin Melanoma (Cell Line: UACC-257) [6]
Bleomycin + Plicamycin DCSHVG5 Bleomycin Melanoma (Cell Line: MALME-3M) [6]
Bortezomib + Plicamycin DCUDL5E Bortezomib Hodgkin lymphoma (Cell Line: L-1236) [4]
Cabazitaxel + Plicamycin DC6MA2T Cabazitaxel Adenocarcinoma (Cell Line: HCC-2998) [4]
Cabazitaxel + Plicamycin DCFKIO7 Cabazitaxel Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Cabazitaxel + Plicamycin DCW4KUL Cabazitaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Cabazitaxel + Plicamycin DC7912S Cabazitaxel Anaplastic large cell lymphoma (Cell Line: SR) [4]
Cabazitaxel + Plicamycin DCBSFP9 Cabazitaxel Astrocytoma (Cell Line: U251) [4]
Cabazitaxel + Plicamycin DCARKRK Cabazitaxel Astrocytoma (Cell Line: SNB-19) [4]
Cabazitaxel + Plicamycin DCQLT1P Cabazitaxel Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Cabazitaxel + Plicamycin DC3APSN Cabazitaxel Clear cell renal cell carcinoma (Cell Line: A498) [4]
Cabazitaxel + Plicamycin DC88NCY Cabazitaxel Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Cabazitaxel + Plicamycin DCRN3ZN Cabazitaxel Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Cabazitaxel + Plicamycin DCZ6FN5 Cabazitaxel Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Cabazitaxel + Plicamycin DCZHY12 Cabazitaxel Glioblastoma (Cell Line: SNB-75) [4]
Cabazitaxel + Plicamycin DCD4UUV Cabazitaxel Glioma (Cell Line: SF-539) [4]
Cabazitaxel + Plicamycin DCY037T Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Cabazitaxel + Plicamycin DCQ2IHU Cabazitaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Cabazitaxel + Plicamycin DC747PX Cabazitaxel Malignant melanoma (Cell Line: UACC62) [4]
Cabazitaxel + Plicamycin DCXXD9Y Cabazitaxel Melanoma (Cell Line: UACC-257) [4]
Cabazitaxel + Plicamycin DCBS5KM Cabazitaxel Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Cabazitaxel + Plicamycin DC4GTW3 Cabazitaxel Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Cabazitaxel + Plicamycin DCBLV1H Cabazitaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Cabazitaxel + Plicamycin DCASK5E Cabazitaxel Carcinoma (Cell Line: MCF7) [5]
Cabazitaxel + Plicamycin DC7Z603 Cabazitaxel Invasive ductal carcinoma (Cell Line: T-47D) [5]
Cabazitaxel + Plicamycin DCI8H5T Cabazitaxel Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Cabazitaxel + Plicamycin DCBZD4E Cabazitaxel Invasive ductal carcinoma (Cell Line: BT-549) [5]
Crizotinib + Plicamycin DCXM143 Crizotinib Adenocarcinoma (Cell Line: DU-145) [4]
Crizotinib + Plicamycin DCKV3NM Crizotinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Crizotinib + Plicamycin DCPVFAH Crizotinib Adenocarcinoma (Cell Line: HCT116) [4]
Crizotinib + Plicamycin DC55L55 Crizotinib Adenocarcinoma (Cell Line: HCC-2998) [4]
Crizotinib + Plicamycin DCHPEDV Crizotinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Crizotinib + Plicamycin DCOS0DF Crizotinib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Crizotinib + Plicamycin DCR0DAO Crizotinib Amelanotic melanoma (Cell Line: M14) [4]
Crizotinib + Plicamycin DC9WV79 Crizotinib Anaplastic large cell lymphoma (Cell Line: SR) [4]
Crizotinib + Plicamycin DCUHW44 Crizotinib Astrocytoma (Cell Line: U251) [4]
Crizotinib + Plicamycin DCT9OYY Crizotinib Astrocytoma (Cell Line: SNB-19) [4]
Crizotinib + Plicamycin DCG16DE Crizotinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Crizotinib + Plicamycin DCHQMJ6 Crizotinib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Crizotinib + Plicamycin DC1J8QM Crizotinib Clear cell renal cell carcinoma (Cell Line: A498) [4]
Crizotinib + Plicamycin DC8E6WP Crizotinib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Crizotinib + Plicamycin DCJUB8I Crizotinib Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Crizotinib + Plicamycin DC8HPW1 Crizotinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Crizotinib + Plicamycin DCIZ3GN Crizotinib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Crizotinib + Plicamycin DC1Y6RV Crizotinib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Crizotinib + Plicamycin DCVPUYT Crizotinib Glioblastoma (Cell Line: SNB-75) [4]
Crizotinib + Plicamycin DC90BL6 Crizotinib Glioma (Cell Line: SF-295) [4]
Crizotinib + Plicamycin DC8VIJI Crizotinib Glioma (Cell Line: SF-268) [4]
Crizotinib + Plicamycin DCSUDOW Crizotinib Glioma (Cell Line: SF-539) [4]
Crizotinib + Plicamycin DC55RQG Crizotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Crizotinib + Plicamycin DCWC2L6 Crizotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Crizotinib + Plicamycin DCNOP70 Crizotinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Crizotinib + Plicamycin DCTCN6L Crizotinib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Crizotinib + Plicamycin DCIUPRB Crizotinib Lung adenocarcinoma (Cell Line: EKVX) [4]
Crizotinib + Plicamycin DCLJEUD Crizotinib Malignant melanoma (Cell Line: UACC62) [4]
Crizotinib + Plicamycin DCLS8EE Crizotinib Melanoma (Cell Line: MALME-3M) [4]
Crizotinib + Plicamycin DCZUU50 Crizotinib Melanoma (Cell Line: UACC-257) [4]
Crizotinib + Plicamycin DC9MK6R Crizotinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Crizotinib + Plicamycin DCEX8AR Crizotinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Crizotinib + Plicamycin DC3MRU4 Crizotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Crizotinib + Plicamycin DC85ME0 Crizotinib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Crizotinib + Plicamycin DC04PH7 Crizotinib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Crizotinib + Plicamycin DCWMO3L Crizotinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Crizotinib + Plicamycin DCJ3GO6 Crizotinib Renal cell carcinoma (Cell Line: UO-31) [4]
Crizotinib + Plicamycin DC7JS5M Crizotinib Renal cell carcinoma (Cell Line: SN12C) [4]
Crizotinib + Plicamycin DCNAOT2 Crizotinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Crizotinib + Plicamycin DC8E6GH Crizotinib Carcinoma (Cell Line: RXF 393) [5]
Crizotinib + Plicamycin DCIGX4H Crizotinib Carcinoma (Cell Line: MCF7) [5]
Crizotinib + Plicamycin DCZ73OY Crizotinib Colon adenocarcinoma (Cell Line: COLO 205) [5]
Crizotinib + Plicamycin DCVCNVM Crizotinib Colon carcinoma (Cell Line: KM12) [5]
Crizotinib + Plicamycin DCQ3VUC Crizotinib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Crizotinib + Plicamycin DCTE2BZ Crizotinib Invasive ductal carcinoma (Cell Line: BT-549) [5]
Crizotinib + Plicamycin DCBOZI7 Crizotinib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Dacarbazine + Plicamycin DCBMLTU Dacarbazine Adenocarcinoma (Cell Line: HCT116) [4]
Dacarbazine + Plicamycin DCQMNR5 Dacarbazine Adenocarcinoma (Cell Line: SW-620) [4]
Dacarbazine + Plicamycin DCKETFR Dacarbazine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Dacarbazine + Plicamycin DCD005P Dacarbazine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Dacarbazine + Plicamycin DCKQ3SE Dacarbazine Amelanotic melanoma (Cell Line: M14) [4]
Dacarbazine + Plicamycin DCXXCSW Dacarbazine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Dacarbazine + Plicamycin DCE4SLQ Dacarbazine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Dacarbazine + Plicamycin DCWWH9Z Dacarbazine Glioma (Cell Line: SF-295) [4]
Dacarbazine + Plicamycin DCYX5HJ Dacarbazine Glioma (Cell Line: SF-539) [4]
Dacarbazine + Plicamycin DCK8LI0 Dacarbazine Melanoma (Cell Line: MALME-3M) [4]
Dacarbazine + Plicamycin DCAEXU1 Dacarbazine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Dacarbazine + Plicamycin DCCNC9T Dacarbazine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Dacarbazine + Plicamycin DCR4MIM Dacarbazine Invasive ductal carcinoma (Cell Line: BT-549) [5]
Dacarbazine + Plicamycin DC5LFK0 Dacarbazine Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Dactinomycin + Plicamycin DCTOJ02 Dactinomycin Colon carcinoma (Cell Line: KM12) [5]
Dactinomycin + Plicamycin DCI8AAU Dactinomycin Adenocarcinoma (Cell Line: DU-145) [6]
Dactinomycin + Plicamycin DCJADZW Dactinomycin Adenocarcinoma (Cell Line: A549) [6]
Dactinomycin + Plicamycin DCT9LCS Dactinomycin Adenocarcinoma (Cell Line: NCIH23) [6]
Dactinomycin + Plicamycin DCK5ER6 Dactinomycin Adenocarcinoma (Cell Line: SW-620) [6]
Dactinomycin + Plicamycin DCA5KX7 Dactinomycin Adenocarcinoma (Cell Line: HCT116) [6]
Dactinomycin + Plicamycin DCGV8K4 Dactinomycin Anaplastic large cell lymphoma (Cell Line: SR) [6]
Dactinomycin + Plicamycin DCYC7M5 Dactinomycin Astrocytoma (Cell Line: SNB-19) [6]
Dactinomycin + Plicamycin DCWUZWC Dactinomycin Clear cell renal cell carcinoma (Cell Line: A498) [6]
Dactinomycin + Plicamycin DCYJF35 Dactinomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [6]
Dactinomycin + Plicamycin DC6GLMW Dactinomycin Glioma (Cell Line: SF-295) [6]
Dactinomycin + Plicamycin DCLTRN1 Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Dactinomycin + Plicamycin DCDP799 Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Dactinomycin + Plicamycin DC66MUC Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Dactinomycin + Plicamycin DCVO1O6 Dactinomycin Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Dactinomycin + Plicamycin DCMYKDW Dactinomycin Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Dactinomycin + Plicamycin DCM98TB Dactinomycin Malignant melanoma (Cell Line: LOX IMVI) [6]
Dactinomycin + Plicamycin DCQA9GN Dactinomycin Prostate carcinoma (Cell Line: PC-3) [6]
Dasatinib + Plicamycin DCJEC96 Dasatinib Adenocarcinoma (Cell Line: DU-145) [4]
Dasatinib + Plicamycin DC0BMH6 Dasatinib Adenocarcinoma (Cell Line: NCIH23) [4]
Dasatinib + Plicamycin DCNZE1F Dasatinib Adenocarcinoma (Cell Line: HCT-15) [4]
Dasatinib + Plicamycin DCQPC2M Dasatinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Dasatinib + Plicamycin DC57V5D Dasatinib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Dasatinib + Plicamycin DCUE413 Dasatinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Dasatinib + Plicamycin DCVK73W Dasatinib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Dasatinib + Plicamycin DC4NIEE Dasatinib Malignant melanoma (Cell Line: UACC62) [4]
Dasatinib + Plicamycin DC1CDGN Dasatinib Melanoma (Cell Line: SK-MEL-2) [4]
Dasatinib + Plicamycin DCVO3DR Dasatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Dasatinib + Plicamycin DCUPFG2 Dasatinib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Dasatinib + Plicamycin DCFF6M7 Dasatinib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Dexrazoxane + Plicamycin DCIFVCJ Dexrazoxane Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Dexrazoxane + Plicamycin DC1CXSU Dexrazoxane Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Dexrazoxane + Plicamycin DCSZUSY Dexrazoxane Anaplastic large cell lymphoma (Cell Line: SR) [4]
Dexrazoxane + Plicamycin DC3V7JA Dexrazoxane Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Dexrazoxane + Plicamycin DC6W5PQ Dexrazoxane Chronic myelogenous leukemia (Cell Line: K-562) [4]
Dexrazoxane + Plicamycin DCMA5UE Dexrazoxane Clear cell renal cell carcinoma (Cell Line: A498) [4]
Dexrazoxane + Plicamycin DCIADZ5 Dexrazoxane Glioma (Cell Line: SF-539) [4]
Dexrazoxane + Plicamycin DCI81IH Dexrazoxane Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Dexrazoxane + Plicamycin DCAFZRW Dexrazoxane Carcinoma (Cell Line: RXF 393) [5]
Dexrazoxane + Plicamycin DCQQ6D4 Dexrazoxane Colon adenocarcinoma (Cell Line: COLO 205) [5]
Dexrazoxane + Plicamycin DCE6P1Q Dexrazoxane Colon carcinoma (Cell Line: KM12) [5]
Dexrazoxane + Plicamycin DCMDXSC Dexrazoxane Invasive ductal carcinoma (Cell Line: BT-549) [5]
Dexrazoxane + Plicamycin DCZE2RW Dexrazoxane Invasive ductal carcinoma (Cell Line: T-47D) [5]
Dexrazoxane + Plicamycin DCZBKKJ Dexrazoxane Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Dexrazoxane + Plicamycin DCPYEDW Dexrazoxane Adenocarcinoma (Cell Line: SW-620) [6]
Dexrazoxane + Plicamycin DC9GSPC Dexrazoxane Adenocarcinoma (Cell Line: HCT116) [6]
Dexrazoxane + Plicamycin DCBKGCV Dexrazoxane High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Dexrazoxane + Plicamycin DCR9ZVA Dexrazoxane Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Dexrazoxane + Plicamycin DC2WA1C Dexrazoxane Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Dexrazoxane + Plicamycin DCO661E Dexrazoxane Melanoma (Cell Line: MALME-3M) [6]
DFN-15 + Plicamycin DCKLX2T DFN-15 Invasive ductal carcinoma (Cell Line: T-47D) [5]
DFN-15 + Plicamycin DC4J5I6 DFN-15 Adenocarcinoma (Cell Line: NCIH23) [6]
DFN-15 + Plicamycin DC8BEKP DFN-15 Adenocarcinoma (Cell Line: HCT116) [6]
DFN-15 + Plicamycin DCN4GKD DFN-15 Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
DFN-15 + Plicamycin DC5TCIL DFN-15 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
DFN-15 + Plicamycin DCOP8LE DFN-15 Melanoma (Cell Line: MALME-3M) [6]
Digitoxin + Plicamycin DCU4HRG Digitoxin Adenocarcinoma (Cell Line: HCC-2998) [4]
Digitoxin + Plicamycin DCPNQ3X Digitoxin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Docetaxel + Plicamycin DC6SU3F Docetaxel Adenocarcinoma (Cell Line: DU-145) [4]
Docetaxel + Plicamycin DC3K3OK Docetaxel Adenocarcinoma (Cell Line: NCIH23) [4]
Docetaxel + Plicamycin DCJGROJ Docetaxel Adenocarcinoma (Cell Line: A549) [4]
Docetaxel + Plicamycin DCITEWQ Docetaxel Adenocarcinoma (Cell Line: HT29) [4]
Docetaxel + Plicamycin DC59IF1 Docetaxel Adenocarcinoma (Cell Line: HCT116) [4]
Docetaxel + Plicamycin DCLZRTY Docetaxel Adenocarcinoma (Cell Line: HCC-2998) [4]
Docetaxel + Plicamycin DC5UKL1 Docetaxel Adenocarcinoma (Cell Line: SW-620) [4]
Docetaxel + Plicamycin DCJR3I9 Docetaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Docetaxel + Plicamycin DCUK6B8 Docetaxel Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Docetaxel + Plicamycin DCXJF0J Docetaxel Amelanotic melanoma (Cell Line: M14) [4]
Docetaxel + Plicamycin DCP92YH Docetaxel Anaplastic large cell lymphoma (Cell Line: SR) [4]
Docetaxel + Plicamycin DCGROZH Docetaxel Astrocytoma (Cell Line: U251) [4]
Docetaxel + Plicamycin DCHQ5HB Docetaxel Astrocytoma (Cell Line: SNB-19) [4]
Docetaxel + Plicamycin DCPYOTD Docetaxel Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Docetaxel + Plicamycin DCYAIN7 Docetaxel Chronic myelogenous leukemia (Cell Line: K-562) [4]
Docetaxel + Plicamycin DCFUUTP Docetaxel Clear cell renal cell carcinoma (Cell Line: A498) [4]
Docetaxel + Plicamycin DC23IUN Docetaxel Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Docetaxel + Plicamycin DCXD051 Docetaxel Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Docetaxel + Plicamycin DC4V0EQ Docetaxel Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Docetaxel + Plicamycin DCNQO0L Docetaxel Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Docetaxel + Plicamycin DC3QPL1 Docetaxel Glioblastoma (Cell Line: SNB-75) [4]
Docetaxel + Plicamycin DCO7ZX1 Docetaxel Glioma (Cell Line: SF-268) [4]
Docetaxel + Plicamycin DCZC0F8 Docetaxel Glioma (Cell Line: SF-539) [4]
Docetaxel + Plicamycin DC68L6I Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Docetaxel + Plicamycin DCL04HW Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Docetaxel + Plicamycin DCARLVQ Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Docetaxel + Plicamycin DCYVB13 Docetaxel Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Docetaxel + Plicamycin DCT2YK7 Docetaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Docetaxel + Plicamycin DCXLBJ9 Docetaxel Lung adenocarcinoma (Cell Line: EKVX) [4]
Docetaxel + Plicamycin DCNS8T1 Docetaxel Lung adenocarcinoma (Cell Line: HOP-62) [4]
Docetaxel + Plicamycin DCL1LA9 Docetaxel Malignant melanoma (Cell Line: LOX IMVI) [4]
Docetaxel + Plicamycin DCT8MBX Docetaxel Malignant melanoma (Cell Line: UACC62) [4]
Docetaxel + Plicamycin DCFKYGM Docetaxel Melanoma (Cell Line: MALME-3M) [4]
Docetaxel + Plicamycin DCDBA47 Docetaxel Melanoma (Cell Line: SK-MEL-2) [4]
Docetaxel + Plicamycin DCQCINX Docetaxel Melanoma (Cell Line: UACC-257) [4]
Docetaxel + Plicamycin DCLCBMQ Docetaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Docetaxel + Plicamycin DCLCHDR Docetaxel Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Docetaxel + Plicamycin DCOV46H Docetaxel Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Docetaxel + Plicamycin DCSCY7L Docetaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Docetaxel + Plicamycin DC6UKJ6 Docetaxel Renal cell carcinoma (Cell Line: SN12C) [4]
Docetaxel + Plicamycin DCYUCCS Docetaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Docetaxel + Plicamycin DCFZ6J5 Docetaxel Carcinoma (Cell Line: RXF 393) [5]
Docetaxel + Plicamycin DCUEJJ1 Docetaxel Carcinoma (Cell Line: MCF7) [5]
Docetaxel + Plicamycin DC68T3T Docetaxel Colon adenocarcinoma (Cell Line: COLO 205) [5]
Docetaxel + Plicamycin DCWB3PR Docetaxel Colon carcinoma (Cell Line: KM12) [5]
Docetaxel + Plicamycin DCTHWH0 Docetaxel Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Docetaxel + Plicamycin DCXWS4S Docetaxel Invasive ductal carcinoma (Cell Line: BT-549) [5]
Epirubicin + Plicamycin DCXJMTQ Epirubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Epirubicin + Plicamycin DC1XM5T Epirubicin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Epirubicin + Plicamycin DCOOD4P Epirubicin Astrocytoma (Cell Line: SNB-19) [4]
Epirubicin + Plicamycin DC6GGW1 Epirubicin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Epirubicin + Plicamycin DCTJQJ3 Epirubicin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Epirubicin + Plicamycin DCGJFPH Epirubicin Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Epirubicin + Plicamycin DCZXV64 Epirubicin Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Epirubicin + Plicamycin DCWDMWY Epirubicin Clear cell renal cell carcinoma (Cell Line: A498) [4]
Epirubicin + Plicamycin DCQ8BYR Epirubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Epirubicin + Plicamycin DC3NJFE Epirubicin Glioblastoma (Cell Line: SNB-75) [4]
Epirubicin + Plicamycin DC4HPZP Epirubicin Glioma (Cell Line: SF-268) [4]
Epirubicin + Plicamycin DC5STQ8 Epirubicin Glioma (Cell Line: SF-295) [4]
Epirubicin + Plicamycin DCZXQ2Y Epirubicin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Epirubicin + Plicamycin DCM5QGF Epirubicin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Epirubicin + Plicamycin DCHWXFQ Epirubicin Renal cell carcinoma (Cell Line: SN12C) [4]
Epirubicin + Plicamycin DC4WAR4 Epirubicin Renal cell carcinoma (Cell Line: UO-31) [4]
Epirubicin + Plicamycin DC3MMPT Epirubicin Carcinoma (Cell Line: RXF 393) [5]
Epirubicin + Plicamycin DCFHZG2 Epirubicin Carcinoma (Cell Line: MCF7) [5]
Epirubicin + Plicamycin DCS4SOO Epirubicin Colon adenocarcinoma (Cell Line: COLO 205) [5]
Epirubicin + Plicamycin DCV7W7E Epirubicin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Epirubicin + Plicamycin DC2H8LI Epirubicin Invasive ductal carcinoma (Cell Line: T-47D) [5]
Epirubicin + Plicamycin DCBXL01 Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Epirubicin + Plicamycin DCYYID2 Epirubicin Adenocarcinoma (Cell Line: DU-145) [6]
Epirubicin + Plicamycin DCUJ7XR Epirubicin Adenocarcinoma (Cell Line: HT29) [6]
Epirubicin + Plicamycin DCYEWYY Epirubicin Adenocarcinoma (Cell Line: HCT-15) [6]
Epirubicin + Plicamycin DCHEJ7P Epirubicin Amelanotic melanoma (Cell Line: M14) [6]
Epirubicin + Plicamycin DCU9PTZ Epirubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Epirubicin + Plicamycin DCC58MZ Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Epirubicin + Plicamycin DCQGSCU Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Epirubicin + Plicamycin DCN5R9V Epirubicin Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Epirubicin + Plicamycin DC8GQNX Epirubicin Lung adenocarcinoma (Cell Line: HOP-62) [6]
Epirubicin + Plicamycin DCMSPFZ Epirubicin Lung adenocarcinoma (Cell Line: EKVX) [6]
Epirubicin + Plicamycin DCK73UI Epirubicin Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Epirubicin + Plicamycin DC1OVDB Epirubicin Malignant melanoma (Cell Line: UACC62) [6]
Epirubicin + Plicamycin DCXRK7Y Epirubicin Malignant melanoma (Cell Line: LOX IMVI) [6]
Epirubicin + Plicamycin DCOER6L Epirubicin Melanoma (Cell Line: MALME-3M) [6]
Epirubicin + Plicamycin DCHXUCR Epirubicin Melanoma (Cell Line: UACC-257) [6]
Epirubicin + Plicamycin DCRYPZD Epirubicin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Epirubicin + Plicamycin DC8X13Q Epirubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Epirubicin + Plicamycin DCIIJJU Epirubicin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Estramustine + Plicamycin DCIBW1D Estramustine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Estramustine + Plicamycin DCPQZK6 Estramustine Carcinoma (Cell Line: MCF7) [5]
Estramustine + Plicamycin DCGLHDL Estramustine Invasive ductal carcinoma (Cell Line: T-47D) [5]
Estramustine + Plicamycin DCP6UYX Estramustine Adenocarcinoma (Cell Line: OVCAR3) [6]
Estramustine + Plicamycin DC3RORH Estramustine Lung adenocarcinoma (Cell Line: EKVX) [6]
Fludarabine + Plicamycin DC2VCGH Fludarabine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Fludarabine + Plicamycin DC1O1RU Fludarabine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Fludarabine + Plicamycin DCYWEOE Fludarabine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Fludarabine + Plicamycin DCHHFMK Fludarabine Adenocarcinoma (Cell Line: NCIH23) [6]
Gefitinib + Plicamycin DCUFMZ3 Gefitinib Adenocarcinoma (Cell Line: DU-145) [4]
Gefitinib + Plicamycin DC89OHM Gefitinib Adenocarcinoma (Cell Line: A549) [4]
Gefitinib + Plicamycin DCTUSDX Gefitinib Adenocarcinoma (Cell Line: NCIH23) [4]
Gefitinib + Plicamycin DCQ8HXE Gefitinib Adenocarcinoma (Cell Line: SW-620) [4]
Gefitinib + Plicamycin DCTOIWA Gefitinib Adenocarcinoma (Cell Line: HCT-15) [4]
Gefitinib + Plicamycin DCH8BFJ Gefitinib Adenocarcinoma (Cell Line: HCC-2998) [4]
Gefitinib + Plicamycin DCZOTFR Gefitinib Adenocarcinoma (Cell Line: HCT116) [4]
Gefitinib + Plicamycin DC9KDW7 Gefitinib Adenocarcinoma (Cell Line: HT29) [4]
Gefitinib + Plicamycin DCSX4NG Gefitinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Gefitinib + Plicamycin DCILU4A Gefitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Gefitinib + Plicamycin DC4LNBP Gefitinib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Gefitinib + Plicamycin DCOYZNF Gefitinib Amelanotic melanoma (Cell Line: M14) [4]
Gefitinib + Plicamycin DCF8J0J Gefitinib Anaplastic large cell lymphoma (Cell Line: SR) [4]
Gefitinib + Plicamycin DCF4218 Gefitinib Astrocytoma (Cell Line: U251) [4]
Gefitinib + Plicamycin DCKM9JR Gefitinib Astrocytoma (Cell Line: SNB-19) [4]
Gefitinib + Plicamycin DCXQC4R Gefitinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Gefitinib + Plicamycin DC37OR9 Gefitinib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Gefitinib + Plicamycin DC6IFPI Gefitinib Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Gefitinib + Plicamycin DCUU37D Gefitinib Clear cell renal cell carcinoma (Cell Line: A498) [4]
Gefitinib + Plicamycin DCEOZLY Gefitinib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Gefitinib + Plicamycin DCXZF6G Gefitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Gefitinib + Plicamycin DCS785L Gefitinib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Gefitinib + Plicamycin DC18VHD Gefitinib Glioma (Cell Line: SF-539) [4]
Gefitinib + Plicamycin DCQH1E7 Gefitinib Glioma (Cell Line: SF-295) [4]
Gefitinib + Plicamycin DC8NLOD Gefitinib Glioma (Cell Line: SF-268) [4]
Gefitinib + Plicamycin DCHF8ER Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Gefitinib + Plicamycin DCBR4DH Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Gefitinib + Plicamycin DCBS1LJ Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Gefitinib + Plicamycin DC4XTOW Gefitinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Gefitinib + Plicamycin DCNJBKC Gefitinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Gefitinib + Plicamycin DCGHE8T Gefitinib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Gefitinib + Plicamycin DCCPK3P Gefitinib Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Gefitinib + Plicamycin DCITRJA Gefitinib Malignant melanoma (Cell Line: UACC62) [4]
Gefitinib + Plicamycin DCLOBCE Gefitinib Malignant melanoma (Cell Line: LOX IMVI) [4]
Gefitinib + Plicamycin DCAW2H7 Gefitinib Melanoma (Cell Line: UACC-257) [4]
Gefitinib + Plicamycin DC4I84G Gefitinib Melanoma (Cell Line: SK-MEL-2) [4]
Gefitinib + Plicamycin DCFKP2A Gefitinib Melanoma (Cell Line: MALME-3M) [4]
Gefitinib + Plicamycin DC0KEXP Gefitinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Gefitinib + Plicamycin DC1G4RC Gefitinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Gefitinib + Plicamycin DCBRGBH Gefitinib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Gefitinib + Plicamycin DCWINL4 Gefitinib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Gefitinib + Plicamycin DCQSDVR Gefitinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Gefitinib + Plicamycin DCGVS4K Gefitinib Renal cell carcinoma (Cell Line: SN12C) [4]
Gefitinib + Plicamycin DCUTD31 Gefitinib Renal cell carcinoma (Cell Line: UO-31) [4]
Gefitinib + Plicamycin DCCVA90 Gefitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Gefitinib + Plicamycin DCXSPF3 Gefitinib Carcinoma (Cell Line: RXF 393) [5]
Gefitinib + Plicamycin DC24KON Gefitinib Carcinoma (Cell Line: MCF7) [5]
Gefitinib + Plicamycin DC0C9PW Gefitinib Colon adenocarcinoma (Cell Line: COLO 205) [5]
Gefitinib + Plicamycin DC74WRB Gefitinib Colon carcinoma (Cell Line: KM12) [5]
Gefitinib + Plicamycin DC0VK6L Gefitinib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Gefitinib + Plicamycin DC85S88 Gefitinib Invasive ductal carcinoma (Cell Line: BT-549) [5]
Gefitinib + Plicamycin DCD12LA Gefitinib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Idarubicin + Plicamycin DCGBX8N Idarubicin Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Idarubicin + Plicamycin DCHVWBD Idarubicin Glioma (Cell Line: SF-268) [4]
Idarubicin + Plicamycin DCKKCQL Idarubicin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Idarubicin + Plicamycin DCINYI6 Idarubicin Adenocarcinoma (Cell Line: HT29) [6]
Indazole derivative 5 + Plicamycin DCUMFTB Indazole derivative 5 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Indazole derivative 5 + Plicamycin DCPAJ95 Indazole derivative 5 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Indazole derivative 5 + Plicamycin DCRHUXF Indazole derivative 5 Anaplastic large cell lymphoma (Cell Line: SR) [4]
Indazole derivative 5 + Plicamycin DC9FAPK Indazole derivative 5 Astrocytoma (Cell Line: SNB-19) [4]
Indazole derivative 5 + Plicamycin DC6VYXF Indazole derivative 5 Chronic myelogenous leukemia (Cell Line: K-562) [4]
Indazole derivative 5 + Plicamycin DCF2XJ0 Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: A498) [4]
Indazole derivative 5 + Plicamycin DC3M1GY Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Indazole derivative 5 + Plicamycin DCB9QWN Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Indazole derivative 5 + Plicamycin DCQBU9J Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Indazole derivative 5 + Plicamycin DCY0AHD Indazole derivative 5 Glioblastoma (Cell Line: SNB-75) [4]
Indazole derivative 5 + Plicamycin DCHPYBC Indazole derivative 5 Glioma (Cell Line: SF-295) [4]
Indazole derivative 5 + Plicamycin DCFJYS8 Indazole derivative 5 Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Indazole derivative 5 + Plicamycin DCI9O4R Indazole derivative 5 Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Indazole derivative 5 + Plicamycin DCFAM6W Indazole derivative 5 Renal cell carcinoma (Cell Line: UO-31) [4]
Indazole derivative 5 + Plicamycin DC4KB76 Indazole derivative 5 Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Indazole derivative 5 + Plicamycin DCNT3XE Indazole derivative 5 Carcinoma (Cell Line: MCF7) [5]
Indazole derivative 5 + Plicamycin DCCAG7O Indazole derivative 5 Colon adenocarcinoma (Cell Line: COLO 205) [5]
Indazole derivative 5 + Plicamycin DC62AHJ Indazole derivative 5 Colon carcinoma (Cell Line: KM12) [5]
Indazole derivative 5 + Plicamycin DCO8X0V Indazole derivative 5 Invasive ductal carcinoma (Cell Line: BT-549) [5]
Indazole derivative 5 + Plicamycin DCK3F0N Indazole derivative 5 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Indazole derivative 5 + Plicamycin DCDMYCJ Indazole derivative 5 Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Indazole derivative 5 + Plicamycin DCZG6WP Indazole derivative 5 Adenocarcinoma (Cell Line: DU-145) [6]
Indazole derivative 5 + Plicamycin DCCCLGJ Indazole derivative 5 Adenocarcinoma (Cell Line: OVCAR3) [6]
Indazole derivative 5 + Plicamycin DC4Q8XF Indazole derivative 5 Adenocarcinoma (Cell Line: HCC-2998) [6]
Indazole derivative 5 + Plicamycin DC659YG Indazole derivative 5 Adenocarcinoma (Cell Line: HT29) [6]
Indazole derivative 5 + Plicamycin DCDCF5O Indazole derivative 5 Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Indazole derivative 5 + Plicamycin DC8EKGK Indazole derivative 5 Amelanotic melanoma (Cell Line: M14) [6]
Indazole derivative 5 + Plicamycin DCW5TKR Indazole derivative 5 Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Indazole derivative 5 + Plicamycin DCHTQRX Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Indazole derivative 5 + Plicamycin DCXFSYB Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Indazole derivative 5 + Plicamycin DCDLKVS Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Indazole derivative 5 + Plicamycin DC1V6R7 Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [6]
Indazole derivative 5 + Plicamycin DC4DQKT Indazole derivative 5 Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Indazole derivative 5 + Plicamycin DCKJGRV Indazole derivative 5 Malignant melanoma (Cell Line: LOX IMVI) [6]
Indazole derivative 5 + Plicamycin DCU5XVY Indazole derivative 5 Melanoma (Cell Line: MALME-3M) [6]
Indazole derivative 5 + Plicamycin DCEHX1L Indazole derivative 5 Melanoma (Cell Line: UACC-257) [6]
Indazole derivative 5 + Plicamycin DC66JV2 Indazole derivative 5 Melanoma (Cell Line: SK-MEL-2) [6]
Indazole derivative 5 + Plicamycin DC3LJKY Indazole derivative 5 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Indazole derivative 5 + Plicamycin DCUTBHH Indazole derivative 5 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Indazole derivative 5 + Plicamycin DC32BYX Indazole derivative 5 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Indazole derivative 5 + Plicamycin DC1XBEP Indazole derivative 5 Prostate carcinoma (Cell Line: PC-3) [6]
JNK-IN-8 + Plicamycin DCR6O9H JNK-IN-8 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
JNK-IN-8 + Plicamycin DCQU193 JNK-IN-8 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
JNK-IN-8 + Plicamycin DC30W15 JNK-IN-8 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
JNK-IN-8 + Plicamycin DC4Z994 JNK-IN-8 Chronic myelogenous leukemia (Cell Line: K-562) [4]
JNK-IN-8 + Plicamycin DCQBYA6 JNK-IN-8 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
JNK-IN-8 + Plicamycin DC13VM3 JNK-IN-8 Plasma cell myeloma (Cell Line: RPMI-8226) [4]
JNK-IN-8 + Plicamycin DC73RRS JNK-IN-8 Renal cell carcinoma (Cell Line: UO-31) [4]
JNK-IN-8 + Plicamycin DCJ5VQZ JNK-IN-8 Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
JNK-IN-8 + Plicamycin DC538EX JNK-IN-8 Carcinoma (Cell Line: RXF 393) [5]
JNK-IN-8 + Plicamycin DCQBZ79 JNK-IN-8 Colon adenocarcinoma (Cell Line: COLO 205) [5]
JNK-IN-8 + Plicamycin DCIVFS0 JNK-IN-8 Invasive ductal carcinoma (Cell Line: BT-549) [5]
JNK-IN-8 + Plicamycin DC0A5GT JNK-IN-8 Invasive ductal carcinoma (Cell Line: HS 578T) [5]
JNK-IN-8 + Plicamycin DCVX36Z JNK-IN-8 Adenocarcinoma (Cell Line: DU-145) [6]
JNK-IN-8 + Plicamycin DCT42ZG JNK-IN-8 Adenocarcinoma (Cell Line: HCT116) [6]
JNK-IN-8 + Plicamycin DC3SVAY JNK-IN-8 Amelanotic melanoma (Cell Line: M14) [6]
JNK-IN-8 + Plicamycin DCM6G76 JNK-IN-8 Large cell lung carcinoma (Cell Line: NCI-H460) [6]
JNK-IN-8 + Plicamycin DC426J8 JNK-IN-8 Lung adenocarcinoma (Cell Line: EKVX) [6]
JNK-IN-8 + Plicamycin DC28G73 JNK-IN-8 Lung adenocarcinoma (Cell Line: NCI-H522) [6]
JNK-IN-8 + Plicamycin DCDRL8M JNK-IN-8 Malignant melanoma (Cell Line: UACC62) [6]
Lapatinib + Plicamycin DCXWDHL Lapatinib Carcinoma (Cell Line: MCF7) [5]
Lapatinib + Plicamycin DCTMUHM Lapatinib Adenocarcinoma (Cell Line: NCIH23) [6]
Lapatinib + Plicamycin DC5U7BN Lapatinib Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Lapatinib + Plicamycin DCUP5BW Lapatinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [6]
Lapatinib + Plicamycin DCT25PK Lapatinib Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Plicamycin DCSRLWD Lenalidomide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Lenalidomide + Plicamycin DC4GZ3L Lenalidomide Glioma (Cell Line: SF-295) [4]
Lenalidomide + Plicamycin DCE2F51 Lenalidomide Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Plicamycin DCGJB2R Lenalidomide Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Lenalidomide + Plicamycin DCOU517 Lenalidomide Carcinoma (Cell Line: RXF 393) [5]
Lenalidomide + Plicamycin DC99LBU Lenalidomide Invasive ductal carcinoma (Cell Line: BT-549) [5]
Lenalidomide + Plicamycin DCPEW12 Lenalidomide Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Lenalidomide + Plicamycin DCDGNVH Lenalidomide Adenocarcinoma (Cell Line: HCC-2998) [6]
Lenalidomide + Plicamycin DCTNZPD Lenalidomide Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Plicamycin DCSKR1I Lenalidomide Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Plicamycin DCJVBK2 Lenalidomide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Lenalidomide + Plicamycin DC4P8S4 Lenalidomide Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Lenalidomide + Plicamycin DC3HPS3 Lenalidomide Melanoma (Cell Line: SK-MEL-2) [6]
Lenalidomide + Plicamycin DCNQ56B Lenalidomide Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Plicamycin DCTOJTU Lenalidomide Melanoma (Cell Line: UACC-257) [6]
Lenalidomide + Plicamycin DCRDTDB Lenalidomide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + Plicamycin DCKJFE4 Lenalidomide Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Letrozole + Plicamycin DCM5O8O Letrozole Adenocarcinoma (Cell Line: A549) [4]
Letrozole + Plicamycin DCFW913 Letrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Letrozole + Plicamycin DC0YJQ3 Letrozole Malignant melanoma (Cell Line: UACC62) [4]
Letrozole + Plicamycin DCX0XXE Letrozole Melanoma (Cell Line: MALME-3M) [4]
Letrozole + Plicamycin DC1N2RZ Letrozole Melanoma (Cell Line: SK-MEL-2) [4]
Letrozole + Plicamycin DCDHS4F Letrozole Colon carcinoma (Cell Line: KM12) [5]
Letrozole + Plicamycin DCWGPL8 Letrozole Invasive ductal carcinoma (Cell Line: T-47D) [5]
LIAROZOLE + Plicamycin DCJ8B5F LIAROZOLE Anaplastic large cell lymphoma (Cell Line: SR) [4]
LIAROZOLE + Plicamycin DCM1H09 LIAROZOLE Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Mechlorethamine + Plicamycin DCRJ2VC Mechlorethamine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Mechlorethamine + Plicamycin DCMUMIE Mechlorethamine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Mechlorethamine + Plicamycin DC616H4 Mechlorethamine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Mechlorethamine + Plicamycin DCEMD40 Mechlorethamine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Mechlorethamine + Plicamycin DCL3K73 Mechlorethamine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Mechlorethamine + Plicamycin DCRX4J5 Mechlorethamine Renal cell carcinoma (Cell Line: UO-31) [4]
Mechlorethamine + Plicamycin DC3SGI7 Mechlorethamine Colon adenocarcinoma (Cell Line: COLO 205) [5]
Mechlorethamine + Plicamycin DC1R2Z7 Mechlorethamine Colon carcinoma (Cell Line: KM12) [5]
Mechlorethamine + Plicamycin DC751JV Mechlorethamine Invasive ductal carcinoma (Cell Line: BT-549) [5]
Mechlorethamine + Plicamycin DC197KT Mechlorethamine Adenocarcinoma (Cell Line: HCT116) [6]
Mechlorethamine + Plicamycin DCU8AR9 Mechlorethamine Amelanotic melanoma (Cell Line: M14) [6]
Mechlorethamine + Plicamycin DCFALYD Mechlorethamine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Mechlorethamine + Plicamycin DCZVFBT Mechlorethamine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Mechlorethamine + Plicamycin DCZ4V9A Mechlorethamine Malignant melanoma (Cell Line: UACC62) [6]
Mechlorethamine + Plicamycin DCRVZW1 Mechlorethamine Melanoma (Cell Line: MALME-3M) [6]
Mechlorethamine + Plicamycin DCOQUWW Mechlorethamine Melanoma (Cell Line: SK-MEL-2) [6]
Picoplatin + Plicamycin DC6M03M Picoplatin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Picoplatin + Plicamycin DC53QTP Picoplatin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Picoplatin + Plicamycin DCQAGLB Picoplatin Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Picoplatin + Plicamycin DCJHH9Q Picoplatin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Picoplatin + Plicamycin DC9U4H5 Picoplatin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Picoplatin + Plicamycin DCL9DJ7 Picoplatin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Picoplatin + Plicamycin DC9VOU3 Picoplatin Carcinoma (Cell Line: RXF 393) [5]
Picoplatin + Plicamycin DCJHSDT Picoplatin Colon carcinoma (Cell Line: KM12) [5]
Picoplatin + Plicamycin DCCJY7Y Picoplatin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Picoplatin + Plicamycin DC1HP05 Picoplatin Invasive ductal carcinoma (Cell Line: T-47D) [5]
Picoplatin + Plicamycin DCGGMYY Picoplatin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Picoplatin + Plicamycin DCTUAWX Picoplatin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Picoplatin + Plicamycin DCM9JS5 Picoplatin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Picoplatin + Plicamycin DC5PE0N Picoplatin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Picoplatin + Plicamycin DCWUXXB Picoplatin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [6]
Picoplatin + Plicamycin DCCDCJ4 Picoplatin Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Picoplatin + Plicamycin DCGJ8U1 Picoplatin Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Picoplatin + Plicamycin DC624CF Picoplatin Malignant melanoma (Cell Line: UACC62) [6]
Picoplatin + Plicamycin DCOUT8S Picoplatin Melanoma (Cell Line: MALME-3M) [6]
Picoplatin + Plicamycin DCK5TKT Picoplatin Melanoma (Cell Line: UACC-257) [6]
Picoplatin + Plicamycin DCCYYQB Picoplatin Melanoma (Cell Line: SK-MEL-2) [6]
Picoplatin + Plicamycin DCB85J3 Picoplatin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Plicamycin + Pentostatin DCBTF8M Pentostatin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Plicamycin + Pentostatin DCRXY29 Pentostatin Astrocytoma (Cell Line: U251) [4]
Plicamycin + Pentostatin DC7YUH9 Pentostatin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Plicamycin + Pentostatin DCAMIDT Pentostatin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Plicamycin + Pentostatin DCTQUY7 Pentostatin Glioma (Cell Line: SF-539) [4]
Plicamycin + Pentostatin DCJU590 Pentostatin Renal cell carcinoma (Cell Line: UO-31) [4]
Plicamycin + Pentostatin DCIOVC4 Pentostatin Renal cell carcinoma (Cell Line: SN12C) [4]
Plicamycin + Fulvestrant DCOZ38Q Fulvestrant Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Plicamycin + Fulvestrant DCXNNAO Fulvestrant Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Plicamycin + Fulvestrant DCITX3Q Fulvestrant Renal cell carcinoma (Cell Line: SN12C) [4]
Plicamycin + Fulvestrant DCQYCF5 Fulvestrant Renal cell carcinoma (Cell Line: UO-31) [4]
Plicamycin + Hepzato DC3L44V Hepzato Astrocytoma (Cell Line: SNB-19) [4]
Plicamycin + Hepzato DC24MUM Hepzato Glioma (Cell Line: SF-295) [4]
Plicamycin + LY335979 DC8K20L LY335979 Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11) [4]
Plicamycin + Ixabepilone DCMRQDO Ixabepilone Glioma (Cell Line: SF-539) [4]
Plicamycin + Ixabepilone DCVKP7D Ixabepilone Glioma (Cell Line: SF-268) [4]
Plicamycin + Ixabepilone DCNF2QI Ixabepilone Renal cell carcinoma (Cell Line: UO-31) [4]
Plicamycin + Ixabepilone DCN9R62 Ixabepilone Renal cell carcinoma (Cell Line: SN12C) [4]
Plicamycin + Cyclophosphamide DCBZQE6 Cyclophosphamide Astrocytoma (Cell Line: SNB-19) [4]
Plicamycin + Cyclophosphamide DCI7H98 Cyclophosphamide Chronic myelogenous leukemia (Cell Line: K-562) [4]
Plicamycin + Cyclophosphamide DCYV5BK Cyclophosphamide Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Plicamycin + Methotrexate DC0QRDW Methotrexate Anaplastic large cell lymphoma (Cell Line: SR) [4]
Plicamycin + Isoniazid DCJWH6E Isoniazid Astrocytoma (Cell Line: SNB-19) [4]
Plicamycin + Isoniazid DCD0DFD Isoniazid Glioma (Cell Line: SF-539) [4]
Plicamycin + Isoniazid DC5U3GI Isoniazid Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Plicamycin + Isoniazid DCP4KP2 Isoniazid Renal cell carcinoma (Cell Line: SN12C) [4]
Plicamycin + Nilotinib DCQQJH1 Nilotinib Anaplastic large cell lymphoma (Cell Line: SR) [4]
Plicamycin + Topetecan DCRA9VD Topetecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Plicamycin + Topetecan DCSFW72 Topetecan Chronic myelogenous leukemia (Cell Line: K-562) [4]
Plicamycin + Pralatrexate DCUK2X3 Pralatrexate Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Plicamycin + Pralatrexate DC033E3 Pralatrexate Astrocytoma (Cell Line: SNB-19) [4]
Plicamycin + Pralatrexate DCQD70K Pralatrexate Clear cell renal cell carcinoma (Cell Line: A498) [4]
Plicamycin + Pralatrexate DC0AKF2 Pralatrexate Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Plicamycin + Pralatrexate DCMEZ0Y Pralatrexate Glioma (Cell Line: SF-539) [4]
Plicamycin + Pralatrexate DCRK1WT Pralatrexate Glioma (Cell Line: SF-268) [4]
Plicamycin + Pralatrexate DCTJ5C9 Pralatrexate Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Plicamycin + Ifosfamide DCLOLGG Ifosfamide Chronic myelogenous leukemia (Cell Line: K-562) [4]
Plicamycin + Ifosfamide DC9M83Y Ifosfamide Clear cell renal cell carcinoma (Cell Line: A498) [4]
Plicamycin + Ifosfamide DCK3J4F Ifosfamide Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Plicamycin + Sirolimus DC293BQ Sirolimus Astrocytoma (Cell Line: U251) [4]
Plicamycin + Sirolimus DC4JTGU Sirolimus Glioma (Cell Line: SF-539) [4]
Plicamycin + Sirolimus DC3CFFS Sirolimus Glioma (Cell Line: SF-268) [4]
Plicamycin + Sirolimus DCCBX8F Sirolimus Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Plicamycin + Sirolimus DCX7L08 Sirolimus Renal cell carcinoma (Cell Line: UO-31) [4]
Plicamycin + Mitomycin DCUSXDA Mitomycin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Plicamycin + Mitomycin DC3IUFS Mitomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Plicamycin + Mitomycin DC0FTIQ Mitomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Plicamycin + Mitomycin DCDQCEN Mitomycin Diffuse large B cell lymphoma (Cell Line: TMD8) [4]
Plicamycin + Mitomycin DCWCX1A Mitomycin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Plicamycin + Altretamine DCVY2PO Altretamine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Plicamycin + Altretamine DC77FHG Altretamine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Plicamycin + Altretamine DCNY327 Altretamine Renal cell carcinoma (Cell Line: SN12C) [4]
Plicamycin + Bleomycin DCT6KQL Bleomycin Glioma (Cell Line: SF-295) [4]
Plicamycin + Bleomycin DCEXPQS Bleomycin Glioma (Cell Line: SF-539) [4]
Plicamycin + Bortezomib DCR6T9R Bortezomib Astrocytoma (Cell Line: U251) [4]
Plicamycin + Bortezomib DCN8E08 Bortezomib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Plicamycin + Valrubicin DCU67JC Valrubicin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Plicamycin + Valrubicin DC1GRLT Valrubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Plicamycin + Valrubicin DCOS4XC Valrubicin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Plicamycin + Valrubicin DC5ABT0 Valrubicin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Plicamycin + Valrubicin DCNYQJF Valrubicin Glioblastoma (Cell Line: SNB-75) [4]
Plicamycin + Valrubicin DCBJ9PH Valrubicin Glioma (Cell Line: SF-539) [4]
Plicamycin + Valrubicin DC3I9VJ Valrubicin Glioma (Cell Line: SF-268) [4]
Plicamycin + Valrubicin DC5KT1B Valrubicin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Plicamycin + Cisplatin DC1MZN6 Cisplatin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Plicamycin + Cisplatin DCODKCZ Cisplatin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Plicamycin + Cisplatin DCA6SSH Cisplatin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Plicamycin + Chlorambucil DCFMYUH Chlorambucil Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Plicamycin + Chlorambucil DCY9LX0 Chlorambucil Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Plicamycin + Chlorambucil DCBPG8U Chlorambucil Chronic myelogenous leukemia (Cell Line: K-562) [4]
Plicamycin + Chlorambucil DC4T49Z Chlorambucil Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Plicamycin + Chlorambucil DCDQ2K1 Chlorambucil Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Plicamycin + ER819762 DCTPEU1 ER819762 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Plicamycin + ER819762 DCBR7Q1 ER819762 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Plicamycin + ER819762 DCC0EA9 ER819762 Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Plicamycin + ER819762 DC4RBVG ER819762 Glioma (Cell Line: SF-295) [4]
Plicamycin + Pomalidomide DCNA6L8 Pomalidomide Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Plicamycin + Pomalidomide DCT1OX5 Pomalidomide Astrocytoma (Cell Line: U251) [4]
Plicamycin + Pomalidomide DC5LIHY Pomalidomide Astrocytoma (Cell Line: SNB-19) [4]
Plicamycin + Pomalidomide DCMEW3W Pomalidomide Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Plicamycin + Pomalidomide DCDUY2I Pomalidomide Clear cell renal cell carcinoma (Cell Line: A498) [4]
Plicamycin + Pomalidomide DCDPZ6C Pomalidomide Renal cell carcinoma (Cell Line: SN12C) [4]
Plicamycin + Vinflunine DCK7XUO Vinflunine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Plicamycin + Vinflunine DCTVI56 Vinflunine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Plicamycin + Vinflunine DC5QJYU Vinflunine Chronic myelogenous leukemia (Cell Line: K-562) [4]
Plicamycin + Vinflunine DCV44QE Vinflunine Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Plicamycin + Vinflunine DCF54TO Vinflunine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Plicamycin + Vinflunine DCZSK1P Vinflunine Glioma (Cell Line: SF-268) [4]
Plicamycin + Vinflunine DCCPXCZ Vinflunine Glioma (Cell Line: SF-539) [4]
Plicamycin + Vinflunine DCTY2VI Vinflunine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Plicamycin + Vinflunine DC8JR4M Vinflunine Renal cell carcinoma (Cell Line: SN12C) [4]
Plicamycin + Elacridar DCUETR3 Elacridar Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11) [4]
Plicamycin + PMID28870136-Compound-43 DCPDQDC PMID28870136-Compound-43 Glioblastoma (Cell Line: SNB-75) [4]
Plicamycin + PMID28870136-Compound-43 DC1ABFG PMID28870136-Compound-43 Glioma (Cell Line: SF-268) [4]
Plicamycin + FORMESTANE DCHRD21 FORMESTANE Renal cell carcinoma (Cell Line: UO-31) [4]
Plicamycin + Busulfan DCFFY0F Busulfan Chronic myelogenous leukemia (Cell Line: K-562) [4]
Plicamycin + Busulfan DCIB3Z3 Busulfan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Plicamycin + Busulfan DCXVJIA Busulfan Glioma (Cell Line: SF-539) [4]
Plicamycin + Busulfan DCUX9QA Busulfan Renal cell carcinoma (Cell Line: UO-31) [4]
Plicamycin + Fulvestrant DC46Z5A Fulvestrant Invasive ductal carcinoma (Cell Line: T-47D) [5]
Plicamycin + Hepzato DCUHPXN Hepzato Carcinoma (Cell Line: MCF7) [5]
Plicamycin + Ixabepilone DC257F1 Ixabepilone Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Plicamycin + Ixabepilone DC06B03 Ixabepilone Colon carcinoma (Cell Line: KM12) [5]
Plicamycin + Ixabepilone DCG4HAM Ixabepilone Invasive ductal carcinoma (Cell Line: T-47D) [5]
Plicamycin + Ixabepilone DCNX3GE Ixabepilone Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Plicamycin + Ixabepilone DCEVVEF Ixabepilone Invasive ductal carcinoma (Cell Line: BT-549) [5]
Plicamycin + Cyclophosphamide DCP9OCU Cyclophosphamide Invasive ductal carcinoma (Cell Line: T-47D) [5]
Plicamycin + Isoniazid DCAWGPP Isoniazid Carcinoma (Cell Line: RXF 393) [5]
Plicamycin + Nilotinib DCZOLEL Nilotinib Colon adenocarcinoma (Cell Line: COLO 205) [5]
Plicamycin + Topetecan DC203AP Topetecan Colon adenocarcinoma (Cell Line: COLO 205) [5]
Plicamycin + Pralatrexate DCEBT01 Pralatrexate Carcinoma (Cell Line: MCF7) [5]
Plicamycin + Pralatrexate DCEYG1D Pralatrexate Invasive ductal carcinoma (Cell Line: BT-549) [5]
Plicamycin + Pralatrexate DCQO5SY Pralatrexate Invasive ductal carcinoma (Cell Line: T-47D) [5]
Plicamycin + Raloxifene DCHPQKH Raloxifene Carcinoma (Cell Line: MCF7) [5]
Plicamycin + Sirolimus DC733JO Sirolimus Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Plicamycin + Mitomycin DCYV58A Mitomycin Colon carcinoma (Cell Line: KM12) [5]
Plicamycin + Altretamine DCQBOUK Altretamine Invasive ductal carcinoma (Cell Line: T-47D) [5]
Plicamycin + Bortezomib DC14RT2 Bortezomib Invasive ductal carcinoma (Cell Line: BT-549) [5]
Plicamycin + Valrubicin DCQL7G7 Valrubicin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Plicamycin + Valrubicin DC16DQ9 Valrubicin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Plicamycin + Chlorambucil DCV0MWR Chlorambucil Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Plicamycin + Chlorambucil DC8UGUM Chlorambucil Invasive ductal carcinoma (Cell Line: T-47D) [5]
Plicamycin + ER819762 DCIC01Q ER819762 Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Plicamycin + ER819762 DCMQNUW ER819762 Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Plicamycin + ER819762 DCCVGXZ ER819762 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Plicamycin + ER819762 DCEUW9P ER819762 Invasive ductal carcinoma (Cell Line: BT-549) [5]
Plicamycin + Pomalidomide DCJ4BTN Pomalidomide Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Plicamycin + Vinflunine DCGM0IW Vinflunine Carcinoma (Cell Line: MCF7) [5]
Plicamycin + Vinflunine DCVZHW0 Vinflunine Colon adenocarcinoma (Cell Line: COLO 205) [5]
Plicamycin + Vinflunine DC96ZF6 Vinflunine Invasive ductal carcinoma (Cell Line: BT-549) [5]
Plicamycin + PMID28870136-Compound-43 DCM7U8E PMID28870136-Compound-43 Colon carcinoma (Cell Line: KM12) [5]
Plicamycin + PMID28870136-Compound-43 DC7332H PMID28870136-Compound-43 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Plicamycin + Busulfan DCLEK33 Busulfan Invasive ductal carcinoma (Cell Line: T-47D) [5]
Plicamycin + Pentostatin DCQNE4V Pentostatin Adenocarcinoma (Cell Line: HT29) [6]
Plicamycin + Pentostatin DCQBMCZ Pentostatin Adenocarcinoma (Cell Line: SW-620) [6]
Plicamycin + Pentostatin DCVBEG5 Pentostatin Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Plicamycin + Pentostatin DCRPL76 Pentostatin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Plicamycin + Fulvestrant DCQDC2O Fulvestrant Adenocarcinoma (Cell Line: OVCAR3) [6]
Plicamycin + Fulvestrant DCZM37A Fulvestrant Adenocarcinoma (Cell Line: A549) [6]
Plicamycin + Fulvestrant DCIQAMR Fulvestrant Adenocarcinoma (Cell Line: HCT116) [6]
Plicamycin + Fulvestrant DCI5DU6 Fulvestrant Malignant melanoma (Cell Line: LOX IMVI) [6]
Plicamycin + Fulvestrant DCETH02 Fulvestrant Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Plicamycin + Ruxolitinib DCZ3T7Z Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [6]
Plicamycin + Hepzato DC5HJKC Hepzato Adenocarcinoma (Cell Line: A549) [6]
Plicamycin + Hepzato DC2QELG Hepzato Adenocarcinoma (Cell Line: HCT-15) [6]
Plicamycin + Hepzato DCQJSYS Hepzato Adenocarcinoma (Cell Line: HCT116) [6]
Plicamycin + Hepzato DC8YEFP Hepzato Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Plicamycin + Hepzato DCM1NQA Hepzato Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Plicamycin + Ixabepilone DCRM5LV Ixabepilone Adenocarcinoma (Cell Line: DU-145) [6]
Plicamycin + Ixabepilone DCSYXRO Ixabepilone Adenocarcinoma (Cell Line: OVCAR3) [6]
Plicamycin + Ixabepilone DCMB17E Ixabepilone Adenocarcinoma (Cell Line: NCIH23) [6]
Plicamycin + Ixabepilone DCLCRGC Ixabepilone Adenocarcinoma (Cell Line: A549) [6]
Plicamycin + Ixabepilone DC220KC Ixabepilone Adenocarcinoma (Cell Line: HCT116) [6]
Plicamycin + Ixabepilone DC4EGJ1 Ixabepilone Adenocarcinoma (Cell Line: SW-620) [6]
Plicamycin + Ixabepilone DCI1QY8 Ixabepilone Adenocarcinoma (Cell Line: HT29) [6]
Plicamycin + Ixabepilone DCZVGX2 Ixabepilone Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Plicamycin + Ixabepilone DCJH2AX Ixabepilone Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Plicamycin + Ixabepilone DCDGJQL Ixabepilone High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Plicamycin + Ixabepilone DC56Y86 Ixabepilone Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Plicamycin + Ixabepilone DC42R4B Ixabepilone Lung adenocarcinoma (Cell Line: HOP-62) [6]
Plicamycin + Ixabepilone DCZ6HFA Ixabepilone Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Plicamycin + Ixabepilone DCQZJWA Ixabepilone Malignant melanoma (Cell Line: UACC62) [6]
Plicamycin + Ixabepilone DCIP6J5 Ixabepilone Melanoma (Cell Line: UACC-257) [6]
Plicamycin + Ixabepilone DCC50IM Ixabepilone Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Plicamycin + Ixabepilone DCDCH3X Ixabepilone Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Plicamycin + Dactinomycin DCKBWA4 Dactinomycin Malignant melanoma (Cell Line: LOX IMVI) [6]
Plicamycin + Cyclophosphamide DCHBCI0 Cyclophosphamide Adenocarcinoma (Cell Line: DU-145) [6]
Plicamycin + Cyclophosphamide DCFWY0B Cyclophosphamide Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Plicamycin + Cyclophosphamide DCSSWTS Cyclophosphamide Melanoma (Cell Line: UACC-257) [6]
Plicamycin + Methotrexate DC723RF Methotrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Plicamycin + Methotrexate DCMDXO2 Methotrexate Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Plicamycin + Methotrexate DC7LI96 Methotrexate Malignant melanoma (Cell Line: UACC62) [6]
Plicamycin + Isoniazid DCVNW9W Isoniazid Malignant melanoma (Cell Line: LOX IMVI) [6]
Plicamycin + Isoniazid DCR0ITM Isoniazid Prostate carcinoma (Cell Line: PC-3) [6]
Plicamycin + Arsenic trioxide DC4SB25 Arsenic trioxide Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Plicamycin + Nilotinib DC6OIAY Nilotinib Adenocarcinoma (Cell Line: OVCAR3) [6]
Plicamycin + Nilotinib DCV481J Nilotinib Adenocarcinoma (Cell Line: HCT116) [6]
Plicamycin + Nilotinib DCP6EAN Nilotinib Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Plicamycin + Nilotinib DCMEW1Z Nilotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Plicamycin + Nilotinib DCFD8Y1 Nilotinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Plicamycin + Triapine DC5W4O1 Triapine Adenocarcinoma (Cell Line: HCC-2998) [6]
Plicamycin + Triapine DCO6O80 Triapine Malignant melanoma (Cell Line: UACC62) [6]
Plicamycin + Topetecan DCXS0RS Topetecan Adenocarcinoma (Cell Line: OVCAR3) [6]
Plicamycin + Topetecan DCAAIY5 Topetecan Adenocarcinoma (Cell Line: HT29) [6]
Plicamycin + Topetecan DCQKMMP Topetecan Adenocarcinoma (Cell Line: HCC-2998) [6]
Plicamycin + Topetecan DC8KDA5 Topetecan Amelanotic melanoma (Cell Line: M14) [6]
Plicamycin + Topetecan DCPV4SI Topetecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Plicamycin + Pralatrexate DCM42IN Pralatrexate Adenocarcinoma (Cell Line: OVCAR3) [6]
Plicamycin + Pralatrexate DCUGH5K Pralatrexate Adenocarcinoma (Cell Line: NCIH23) [6]
Plicamycin + Pralatrexate DC2K0G8 Pralatrexate Adenocarcinoma (Cell Line: HCC-2998) [6]
Plicamycin + Pralatrexate DCIHV63 Pralatrexate Adenocarcinoma (Cell Line: HCT-15) [6]
Plicamycin + Pralatrexate DC42RNM Pralatrexate Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Plicamycin + Pralatrexate DCLZK63 Pralatrexate Lung adenocarcinoma (Cell Line: EKVX) [6]
Plicamycin + Pralatrexate DC7Y3R0 Pralatrexate Melanoma (Cell Line: MALME-3M) [6]
Plicamycin + Pralatrexate DCMZ2ZO Pralatrexate Melanoma (Cell Line: SK-MEL-2) [6]
Plicamycin + Pralatrexate DCOX30U Pralatrexate Non-small cell lung carcinoma (Cell Line: HOP-92) [6]
Plicamycin + Pralatrexate DC2N53J Pralatrexate Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Plicamycin + Ifosfamide DC0ZAZG Ifosfamide Adenocarcinoma (Cell Line: DU-145) [6]
Plicamycin + Ifosfamide DC9ERDN Ifosfamide Adenocarcinoma (Cell Line: HCC-2998) [6]
Plicamycin + Ifosfamide DCYWSSY Ifosfamide Adenocarcinoma (Cell Line: HCT116) [6]
Plicamycin + Ifosfamide DCK1VQW Ifosfamide Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Plicamycin + Ifosfamide DC1N3G8 Ifosfamide Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Plicamycin + Ifosfamide DCAWZ68 Ifosfamide Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Plicamycin + Ifosfamide DC7JI7Q Ifosfamide Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Plicamycin + Raloxifene DCHVZO7 Raloxifene Melanoma (Cell Line: MALME-3M) [6]
Plicamycin + Raloxifene DCQ3KTO Raloxifene Melanoma (Cell Line: UACC-257) [6]
Plicamycin + Bendamustine hydrochloride DCL01FG Bendamustine hydrochloride Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Plicamycin + Sirolimus DCR5UCP Sirolimus Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Plicamycin + Sirolimus DCOGK6P Sirolimus High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Plicamycin + Sirolimus DCE2WCT Sirolimus High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Plicamycin + Sirolimus DCG4464 Sirolimus High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [6]
Plicamycin + Sirolimus DCPGRHR Sirolimus Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Plicamycin + Sirolimus DCLSJIB Sirolimus Prostate carcinoma (Cell Line: PC-3) [6]
Plicamycin + Mitomycin DCLIJ97 Mitomycin Melanoma (Cell Line: UACC-257) [6]
Plicamycin + Mitomycin DC7TU2V Mitomycin Melanoma (Cell Line: MALME-3M) [6]
Plicamycin + Mitomycin DCJRTRC Mitomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Plicamycin + Altretamine DC9QBPB Altretamine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Plicamycin + Altretamine DCPIOP1 Altretamine Malignant melanoma (Cell Line: LOX IMVI) [6]
Plicamycin + Bleomycin DCRA84O Bleomycin Adenocarcinoma (Cell Line: A549) [6]
Plicamycin + Bleomycin DCD4IIN Bleomycin Adenocarcinoma (Cell Line: HCC-2998) [6]
Plicamycin + Bleomycin DC9765K Bleomycin Adenocarcinoma (Cell Line: HT29) [6]
Plicamycin + Bleomycin DCHK17X Bleomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Plicamycin + Bleomycin DCFLHKX Bleomycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Plicamycin + Bortezomib DCG1USW Bortezomib Adenocarcinoma (Cell Line: DU-145) [6]
Plicamycin + Bortezomib DCHR9MN Bortezomib Adenocarcinoma (Cell Line: OVCAR3) [6]
Plicamycin + Bortezomib DCE5Z6G Bortezomib Adenocarcinoma (Cell Line: SW-620) [6]
Plicamycin + Bortezomib DCLC10A Bortezomib Amelanotic melanoma (Cell Line: M14) [6]
Plicamycin + Bortezomib DC0VHMX Bortezomib Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Plicamycin + Bortezomib DC7SM9T Bortezomib Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Plicamycin + Bortezomib DCKF1FL Bortezomib Malignant melanoma (Cell Line: UACC62) [6]
Plicamycin + Bortezomib DC7M49C Bortezomib Malignant melanoma (Cell Line: LOX IMVI) [6]
Plicamycin + Bortezomib DC5H5T1 Bortezomib Melanoma (Cell Line: UACC-257) [6]
Plicamycin + Bortezomib DCEIC9S Bortezomib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Plicamycin + Valrubicin DCR95X5 Valrubicin Adenocarcinoma (Cell Line: SW-620) [6]
Plicamycin + Valrubicin DCVQWJQ Valrubicin Adenocarcinoma (Cell Line: HCT116) [6]
Plicamycin + Valrubicin DCCPQAN Valrubicin Adenocarcinoma (Cell Line: HCT-15) [6]
Plicamycin + Valrubicin DCA3LMJ Valrubicin Amelanotic melanoma (Cell Line: M14) [6]
Plicamycin + Valrubicin DCBDBVE Valrubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Plicamycin + Valrubicin DCSVIGW Valrubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Plicamycin + Valrubicin DCR5EDM Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Plicamycin + Valrubicin DCV02ZH Valrubicin Lung adenocarcinoma (Cell Line: HOP-62) [6]
Plicamycin + Valrubicin DC62ZF2 Valrubicin Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Plicamycin + Valrubicin DC5MYCQ Valrubicin Malignant melanoma (Cell Line: UACC62) [6]
Plicamycin + Valrubicin DCKNM6V Valrubicin Malignant melanoma (Cell Line: LOX IMVI) [6]
Plicamycin + Valrubicin DC69ARK Valrubicin Melanoma (Cell Line: MALME-3M) [6]
Plicamycin + Valrubicin DC2RBJA Valrubicin Melanoma (Cell Line: SK-MEL-2) [6]
Plicamycin + Valrubicin DCSJVDW Valrubicin Melanoma (Cell Line: UACC-257) [6]
Plicamycin + Valrubicin DCKG4T6 Valrubicin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Plicamycin + Valrubicin DCQ1BPG Valrubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Plicamycin + Valrubicin DC4O861 Valrubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Plicamycin + Cisplatin DCD9BOZ Cisplatin Adenocarcinoma (Cell Line: HCT116) [6]
Plicamycin + Cisplatin DCODEWG Cisplatin Malignant melanoma (Cell Line: LOX IMVI) [6]
Plicamycin + Chlorambucil DC0NGWR Chlorambucil Adenocarcinoma (Cell Line: HCT116) [6]
Plicamycin + Chlorambucil DCZPIWH Chlorambucil High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Plicamycin + Chlorambucil DCLVOU2 Chlorambucil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Plicamycin + ER819762 DCE1HF6 ER819762 Adenocarcinoma (Cell Line: HCT-15) [6]
Plicamycin + ER819762 DCLJXU3 ER819762 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Plicamycin + ER819762 DCQLR7E ER819762 Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Plicamycin + ER819762 DCCV2TV ER819762 Malignant melanoma (Cell Line: LOX IMVI) [6]
Plicamycin + ER819762 DCWYBJH ER819762 Melanoma (Cell Line: MALME-3M) [6]
Plicamycin + Pomalidomide DC3VV45 Pomalidomide Adenocarcinoma (Cell Line: NCIH23) [6]
Plicamycin + Vinflunine DC8O2OL Vinflunine Adenocarcinoma (Cell Line: DU-145) [6]
Plicamycin + Vinflunine DC5PYG2 Vinflunine Adenocarcinoma (Cell Line: OVCAR3) [6]
Plicamycin + Vinflunine DCDCUXO Vinflunine Adenocarcinoma (Cell Line: A549) [6]
Plicamycin + Vinflunine DC4JOQM Vinflunine Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Plicamycin + Vinflunine DC8ZX2E Vinflunine Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Plicamycin + Vinflunine DCT4SIP Vinflunine Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Plicamycin + Vinflunine DC5G2SS Vinflunine Melanoma (Cell Line: SK-MEL-2) [6]
Plicamycin + Vinflunine DCOQLZV Vinflunine Melanoma (Cell Line: UACC-257) [6]
Plicamycin + Vinflunine DCY3LBW Vinflunine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Plicamycin + Vinflunine DCV3CVY Vinflunine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Plicamycin + Vinflunine DCXXO7N Vinflunine Prostate carcinoma (Cell Line: PC-3) [6]
Plicamycin + Mepacrine DC5JZI5 Mepacrine Adenocarcinoma (Cell Line: SW-620) [6]
Plicamycin + Mepacrine DCCJPXT Mepacrine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Plicamycin + PMID28870136-Compound-43 DCKX46U PMID28870136-Compound-43 Adenocarcinoma (Cell Line: HCT-15) [6]
Plicamycin + PMID28870136-Compound-43 DC0FIMY PMID28870136-Compound-43 Adenocarcinoma (Cell Line: SW-620) [6]
Plicamycin + PMID28870136-Compound-43 DC3XC3P PMID28870136-Compound-43 Adenocarcinoma (Cell Line: HT29) [6]
Plicamycin + PMID28870136-Compound-43 DC9HVK7 PMID28870136-Compound-43 Amelanotic melanoma (Cell Line: M14) [6]
Plicamycin + FORMESTANE DCBLS4D FORMESTANE Adenocarcinoma (Cell Line: OVCAR3) [6]
Plicamycin + FORMESTANE DCK7AYS FORMESTANE Adenocarcinoma (Cell Line: NCIH23) [6]
Plicamycin + FORMESTANE DCV9LIJ FORMESTANE Adenocarcinoma (Cell Line: HCT-15) [6]
Plicamycin + FORMESTANE DCUYZ67 FORMESTANE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Plicamycin + FORMESTANE DC3S8QV FORMESTANE Melanoma (Cell Line: SK-MEL-2) [6]
Plicamycin + FORMESTANE DC7Y5DS FORMESTANE Non-small cell lung carcinoma (Cell Line: HOP-92) [6]
Plicamycin + Busulfan DC6NUZ8 Busulfan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
PMID28460551-Compound-2 + Plicamycin DCFLKXE PMID28460551-Compound-2 Astrocytoma (Cell Line: SNB-19) [4]
PMID28460551-Compound-2 + Plicamycin DC3OCRL PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HCC-2998) [6]
Raloxifene + Plicamycin DCUUWEB Raloxifene Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Raloxifene + Plicamycin DC0VRBE Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Raloxifene + Plicamycin DC1HCMI Raloxifene Anaplastic large cell lymphoma (Cell Line: SR) [4]
Raloxifene + Plicamycin DC09HHD Raloxifene Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Raloxifene + Plicamycin DCC6K8Y Raloxifene Chronic myelogenous leukemia (Cell Line: K-562) [4]
Raloxifene + Plicamycin DC22SQP Raloxifene Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Raloxifene + Plicamycin DC7TSFW Raloxifene Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Raloxifene + Plicamycin DCA7TFM Raloxifene Glioblastoma (Cell Line: SNB-75) [4]
Raloxifene + Plicamycin DCIK646 Raloxifene Glioma (Cell Line: SF-539) [4]
Raloxifene + Plicamycin DCD9V8Q Raloxifene Glioma (Cell Line: SF-268) [4]
Raloxifene + Plicamycin DCYSBJ0 Raloxifene Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Raloxifene + Plicamycin DCOLUJ2 Raloxifene Renal cell carcinoma (Cell Line: SN12C) [4]
Raloxifene + Plicamycin DCZHEKG Raloxifene Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Raloxifene + Plicamycin DC51BBS Raloxifene Carcinoma (Cell Line: RXF 393) [5]
Raloxifene + Plicamycin DCPFTMU Raloxifene Colon adenocarcinoma (Cell Line: COLO 205) [5]
Raloxifene + Plicamycin DCBQOVE Raloxifene Colon carcinoma (Cell Line: KM12) [5]
Raloxifene + Plicamycin DCIGNV8 Raloxifene Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Raloxifene + Plicamycin DCCFFCC Raloxifene Invasive ductal carcinoma (Cell Line: BT-549) [5]
Raloxifene + Plicamycin DCE8N9U Raloxifene Adenocarcinoma (Cell Line: NCIH23) [6]
Raloxifene + Plicamycin DCUM9M6 Raloxifene Adenocarcinoma (Cell Line: A549) [6]
Raloxifene + Plicamycin DCOUZUT Raloxifene Adenocarcinoma (Cell Line: HCT116) [6]
Raloxifene + Plicamycin DC1D11H Raloxifene Adenocarcinoma (Cell Line: SW-620) [6]
Raloxifene + Plicamycin DCRYFOB Raloxifene Adenocarcinoma (Cell Line: HCC-2998) [6]
Raloxifene + Plicamycin DC3GRGR Raloxifene Adenocarcinoma (Cell Line: HT29) [6]
Raloxifene + Plicamycin DCVAQVT Raloxifene Amelanotic melanoma (Cell Line: M14) [6]
Raloxifene + Plicamycin DCXINQ3 Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Raloxifene + Plicamycin DC1ABVZ Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Raloxifene + Plicamycin DCFPRDH Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [6]
Raloxifene + Plicamycin DCAUQ1P Raloxifene Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Raloxifene + Plicamycin DCDWJ9S Raloxifene Lung adenocarcinoma (Cell Line: HOP-62) [6]
Raloxifene + Plicamycin DC544CQ Raloxifene Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Raloxifene + Plicamycin DCFK2GI Raloxifene Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Raloxifene + Plicamycin DCBYAET Raloxifene Malignant melanoma (Cell Line: LOX IMVI) [6]
Raloxifene + Plicamycin DC0E3AZ Raloxifene Melanoma (Cell Line: SK-MEL-2) [6]
Raloxifene + Plicamycin DCXL4SY Raloxifene Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Raloxifene + Plicamycin DC10ZO1 Raloxifene Prostate carcinoma (Cell Line: PC-3) [6]
Romidepsin + Plicamycin DC9DG4T Romidepsin Glioma (Cell Line: SF-539) [4]
Romidepsin + Plicamycin DCI074Q Romidepsin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Romidepsin + Plicamycin DC3UMUM Romidepsin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Romidepsin + Plicamycin DCR5HCA Romidepsin Adenocarcinoma (Cell Line: HCT-15) [6]
Romidepsin + Plicamycin DCFKHMP Romidepsin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Romidepsin + Plicamycin DC37EXU Romidepsin Melanoma (Cell Line: MALME-3M) [6]
Romidepsin + Plicamycin DCZ8L94 Romidepsin Melanoma (Cell Line: SK-MEL-2) [6]
Ruxolitinib + Plicamycin DCAK2AJ Ruxolitinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Ruxolitinib + Plicamycin DCVQCXX Ruxolitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Ruxolitinib + Plicamycin DC7I3LT Ruxolitinib Anaplastic large cell lymphoma (Cell Line: SR) [4]
Ruxolitinib + Plicamycin DCMRJUI Ruxolitinib Astrocytoma (Cell Line: U251) [4]
Ruxolitinib + Plicamycin DCP0UVE Ruxolitinib Astrocytoma (Cell Line: SNB-19) [4]
Ruxolitinib + Plicamycin DCSZ29A Ruxolitinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Ruxolitinib + Plicamycin DCT8TVE Ruxolitinib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Ruxolitinib + Plicamycin DCMGNCV Ruxolitinib Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Ruxolitinib + Plicamycin DCYJKW4 Ruxolitinib Clear cell renal cell carcinoma (Cell Line: A498) [4]
Ruxolitinib + Plicamycin DC0MDOV Ruxolitinib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Ruxolitinib + Plicamycin DCN1A5J Ruxolitinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Ruxolitinib + Plicamycin DCFUV3H Ruxolitinib Glioma (Cell Line: SF-539) [4]
Ruxolitinib + Plicamycin DCOXTVC Ruxolitinib Glioma (Cell Line: SF-295) [4]
Ruxolitinib + Plicamycin DCFL78I Ruxolitinib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Ruxolitinib + Plicamycin DC46V0X Ruxolitinib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Ruxolitinib + Plicamycin DC6XBKU Ruxolitinib Carcinoma (Cell Line: MCF7) [5]
Ruxolitinib + Plicamycin DC4G2QL Ruxolitinib Colon adenocarcinoma (Cell Line: COLO 205) [5]
Ruxolitinib + Plicamycin DC5BO42 Ruxolitinib Colon carcinoma (Cell Line: KM12) [5]
Ruxolitinib + Plicamycin DC29QEU Ruxolitinib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Ruxolitinib + Plicamycin DCR4RZQ Ruxolitinib Invasive ductal carcinoma (Cell Line: BT-549) [5]
Ruxolitinib + Plicamycin DCDFJDH Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Ruxolitinib + Plicamycin DCROKN8 Ruxolitinib Adenocarcinoma (Cell Line: OVCAR3) [6]
Ruxolitinib + Plicamycin DC47ZNK Ruxolitinib Adenocarcinoma (Cell Line: SW-620) [6]
Ruxolitinib + Plicamycin DCI2M9Q Ruxolitinib Adenocarcinoma (Cell Line: HCT-15) [6]
Ruxolitinib + Plicamycin DC0848B Ruxolitinib Adenocarcinoma (Cell Line: HCT116) [6]
Ruxolitinib + Plicamycin DCL0QDL Ruxolitinib Adenocarcinoma (Cell Line: HCC-2998) [6]
Ruxolitinib + Plicamycin DCYYZBV Ruxolitinib Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Ruxolitinib + Plicamycin DCD1MDI Ruxolitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Ruxolitinib + Plicamycin DC9YSLR Ruxolitinib Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Ruxolitinib + Plicamycin DCULFUI Ruxolitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Ruxolitinib + Plicamycin DC0QRAK Ruxolitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Ruxolitinib + Plicamycin DCS3AML Ruxolitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Ruxolitinib + Plicamycin DCFY4S1 Ruxolitinib Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Ruxolitinib + Plicamycin DCK0CZ0 Ruxolitinib Melanoma (Cell Line: UACC-257) [6]
Ruxolitinib + Plicamycin DCB9JW5 Ruxolitinib Melanoma (Cell Line: SK-MEL-2) [6]
Ruxolitinib + Plicamycin DC2XXRV Ruxolitinib Melanoma (Cell Line: MALME-3M) [6]
Ruxolitinib + Plicamycin DCZSVC1 Ruxolitinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Ruxolitinib + Plicamycin DC700ZP Ruxolitinib Non-small cell lung carcinoma (Cell Line: HOP-92) [6]
Ruxolitinib + Plicamycin DCA079H Ruxolitinib Prostate carcinoma (Cell Line: PC-3) [6]
Sapanisertib + Plicamycin DCMH3JA Sapanisertib Hodgkin lymphoma (Cell Line: L-1236) [6]
SCH 727965 + Plicamycin DCODDKT SCH 727965 Glioma (Cell Line: SF-295) [4]
SCH 727965 + Plicamycin DCWFVW1 SCH 727965 Glioma (Cell Line: SF-268) [4]
SCH 727965 + Plicamycin DC0YANM SCH 727965 Plasma cell myeloma (Cell Line: RPMI-8226) [4]
SCH 727965 + Plicamycin DCMAAYH SCH 727965 Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
SCH 727965 + Plicamycin DCLXN1R SCH 727965 Adenocarcinoma (Cell Line: HCC-2998) [6]
SCH 727965 + Plicamycin DC1JZD7 SCH 727965 Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
SCH 727965 + Plicamycin DCYONGQ SCH 727965 Hodgkin lymphoma (Cell Line: L-1236) [6]
SCH 727965 + Plicamycin DC7HGEQ SCH 727965 Lung adenocarcinoma (Cell Line: HOP-62) [6]
SCH 727965 + Plicamycin DCRA9IY SCH 727965 Melanoma (Cell Line: UACC-257) [6]
SCH 727965 + Plicamycin DCEGF2U SCH 727965 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Sorafenib + Plicamycin DCX49U2 Sorafenib Adenocarcinoma (Cell Line: OVCAR3) [4]
Sorafenib + Plicamycin DCV986K Sorafenib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Sorafenib + Plicamycin DC60YUW Sorafenib Amelanotic melanoma (Cell Line: M14) [4]
Sorafenib + Plicamycin DCTTPOF Sorafenib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Sorafenib + Plicamycin DCHVR3U Sorafenib Anaplastic large cell lymphoma (Cell Line: SR) [4]
Sorafenib + Plicamycin DCKFCN0 Sorafenib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Sorafenib + Plicamycin DCLUYBJ Sorafenib Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Sorafenib + Plicamycin DCKZ8EG Sorafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Sorafenib + Plicamycin DCQF6W1 Sorafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Sorafenib + Plicamycin DCLHQIT Sorafenib Malignant melanoma (Cell Line: LOX IMVI) [4]
Sorafenib + Plicamycin DCJ9B5W Sorafenib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Sorafenib + Plicamycin DCP2I4Z Sorafenib Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Sorafenib + Plicamycin DCGPLRG Sorafenib Colon carcinoma (Cell Line: KM12) [5]
SY-1425 + Plicamycin DCS9RMN SY-1425 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
SY-1425 + Plicamycin DC798ED SY-1425 Astrocytoma (Cell Line: U251) [4]
SY-1425 + Plicamycin DCJGGDS SY-1425 Chronic myelogenous leukemia (Cell Line: K-562) [4]
SY-1425 + Plicamycin DC9U88D SY-1425 Glioblastoma (Cell Line: SNB-75) [4]
SY-1425 + Plicamycin DC0GGED SY-1425 Adenocarcinoma (Cell Line: NCIH23) [6]
SY-1425 + Plicamycin DCBE4ES SY-1425 Adenocarcinoma (Cell Line: A549) [6]
SY-1425 + Plicamycin DC4JOOX SY-1425 Adenocarcinoma (Cell Line: HT29) [6]
SY-1425 + Plicamycin DCYBDGA SY-1425 Adenocarcinoma (Cell Line: HCC-2998) [6]
SY-1425 + Plicamycin DCGOD7P SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
SY-1425 + Plicamycin DCZYG5N SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
SY-1425 + Plicamycin DC7IXDX SY-1425 Lung adenocarcinoma (Cell Line: NCI-H522) [6]
SY-1425 + Plicamycin DC3C4I0 SY-1425 Melanoma (Cell Line: MALME-3M) [6]
SY-1425 + Plicamycin DCD05FH SY-1425 Melanoma (Cell Line: SK-MEL-2) [6]
SY-1425 + Plicamycin DCYI6L3 SY-1425 Prostate carcinoma (Cell Line: PC-3) [6]
Taxol + Plicamycin DCYHN6O Taxol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Taxol + Plicamycin DCSXTP0 Taxol Anaplastic large cell lymphoma (Cell Line: SR) [4]
Taxol + Plicamycin DCDC5O7 Taxol Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Taxol + Plicamycin DCMJOXQ Taxol Chronic myelogenous leukemia (Cell Line: K-562) [4]
Taxol + Plicamycin DCL4Z7F Taxol Clear cell renal cell carcinoma (Cell Line: A498) [4]
Taxol + Plicamycin DCKW2MV Taxol Glioblastoma (Cell Line: SNB-75) [4]
Taxol + Plicamycin DCSIN75 Taxol Glioma (Cell Line: SF-539) [4]
Taxol + Plicamycin DC3XFH5 Taxol Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Taxol + Plicamycin DC1ZGE9 Taxol Carcinoma (Cell Line: RXF 393) [5]
Taxol + Plicamycin DCU7MOJ Taxol Carcinoma (Cell Line: MCF7) [5]
Taxol + Plicamycin DCRFWH0 Taxol Colon carcinoma (Cell Line: KM12) [5]
Taxol + Plicamycin DC3ONFM Taxol Invasive ductal carcinoma (Cell Line: BT-549) [5]
Taxol + Plicamycin DCUZACQ Taxol Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Taxol + Plicamycin DC7VPE0 Taxol Adenocarcinoma (Cell Line: DU-145) [6]
Taxol + Plicamycin DC86HIN Taxol Adenocarcinoma (Cell Line: A549) [6]
Taxol + Plicamycin DCLNKO8 Taxol Adenocarcinoma (Cell Line: HCT116) [6]
Taxol + Plicamycin DCAGCHC Taxol Adenocarcinoma (Cell Line: SW-620) [6]
Taxol + Plicamycin DCX8VYZ Taxol Adenocarcinoma (Cell Line: HCC-2998) [6]
Taxol + Plicamycin DCV8S3U Taxol Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Taxol + Plicamycin DCJ1IHX Taxol Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Taxol + Plicamycin DCEAN0G Taxol Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Taxol + Plicamycin DC9SA5G Taxol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Taxol + Plicamycin DCT1NJN Taxol Lung adenocarcinoma (Cell Line: HOP-62) [6]
Taxol + Plicamycin DCMKTHX Taxol Malignant melanoma (Cell Line: LOX IMVI) [6]
Taxol + Plicamycin DCPCIHF Taxol Melanoma (Cell Line: UACC-257) [6]
Taxol + Plicamycin DC0ME06 Taxol Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Taxol + Plicamycin DC7Q6KU Taxol Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
TEM + Plicamycin DCH5BPD TEM Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
TEM + Plicamycin DCNMXK8 TEM Astrocytoma (Cell Line: SNB-19) [4]
TEM + Plicamycin DCFRU0Y TEM Glioblastoma (Cell Line: SNB-75) [4]
TEM + Plicamycin DCB6WIR TEM Glioma (Cell Line: SF-539) [4]
TEM + Plicamycin DC11NMH TEM Glioma (Cell Line: SF-295) [4]
TEM + Plicamycin DCCLU9M TEM Plasma cell myeloma (Cell Line: RPMI-8226) [4]
TEM + Plicamycin DCEL0MW TEM Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
TEM + Plicamycin DC9SNV1 TEM Carcinoma (Cell Line: RXF 393) [5]
TEM + Plicamycin DCOFKUM TEM Invasive ductal carcinoma (Cell Line: BT-549) [5]
TEM + Plicamycin DCP4H8S TEM Adenocarcinoma (Cell Line: OVCAR3) [6]
TEM + Plicamycin DC5YM0W TEM Adenocarcinoma (Cell Line: A549) [6]
TEM + Plicamycin DC4XXKP TEM Adenocarcinoma (Cell Line: HCT116) [6]
TEM + Plicamycin DCNLG8M TEM Adenocarcinoma (Cell Line: HT29) [6]
TEM + Plicamycin DCUQ0MS TEM Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
TEM + Plicamycin DC209IE TEM High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [6]
TEM + Plicamycin DCB90HT TEM Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
TEM + Plicamycin DCNBSHT TEM Melanoma (Cell Line: MALME-3M) [6]
TEM + Plicamycin DCP7XKZ TEM Melanoma (Cell Line: UACC-257) [6]
TEM + Plicamycin DC8HEOG TEM Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
TEM + Plicamycin DC6JBOK TEM Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Terameprocol + Plicamycin DCFMKQ0 Terameprocol Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Terameprocol + Plicamycin DCGMU0I Terameprocol Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Terameprocol + Plicamycin DCNGR58 Terameprocol Renal cell carcinoma (Cell Line: SN12C) [4]
Terameprocol + Plicamycin DCFG3ZG Terameprocol Carcinoma (Cell Line: RXF 393) [5]
Terameprocol + Plicamycin DC6SICZ Terameprocol Colon carcinoma (Cell Line: KM12) [5]
Terameprocol + Plicamycin DC5TS2A Terameprocol Invasive ductal carcinoma (Cell Line: BT-549) [5]
Terameprocol + Plicamycin DC8N6HM Terameprocol Adenocarcinoma (Cell Line: OVCAR3) [6]
Terameprocol + Plicamycin DCNO67S Terameprocol Adenocarcinoma (Cell Line: A549) [6]
Terameprocol + Plicamycin DCA1X0C Terameprocol Adenocarcinoma (Cell Line: HCT116) [6]
Terameprocol + Plicamycin DCHQQ2D Terameprocol Adenocarcinoma (Cell Line: SW-620) [6]
Terameprocol + Plicamycin DCIOUEH Terameprocol Adenocarcinoma (Cell Line: HT29) [6]
Terameprocol + Plicamycin DCRB2WP Terameprocol Amelanotic melanoma (Cell Line: M14) [6]
Terameprocol + Plicamycin DCV1IUB Terameprocol Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Terameprocol + Plicamycin DCC4DMF Terameprocol Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Terameprocol + Plicamycin DCQLD62 Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Terameprocol + Plicamycin DC1A1MT Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [6]
Terameprocol + Plicamycin DCYV82U Terameprocol Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Terameprocol + Plicamycin DCE0FSS Terameprocol Lung adenocarcinoma (Cell Line: HOP-62) [6]
Terameprocol + Plicamycin DCB2T51 Terameprocol Malignant melanoma (Cell Line: UACC62) [6]
Terameprocol + Plicamycin DCCLIO4 Terameprocol Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Terameprocol + Plicamycin DCRYMVF Terameprocol Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Terameprocol + Plicamycin DCRH23D Terameprocol Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Thioguanine + Plicamycin DCYS8YP Thioguanine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Thioguanine + Plicamycin DC26IKP Thioguanine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Thioguanine + Plicamycin DCHB204 Thioguanine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Thioguanine + Plicamycin DCFV82K Thioguanine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Thioguanine + Plicamycin DCQN5TX Thioguanine Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Thioguanine + Plicamycin DC9G5VL Thioguanine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Thioguanine + Plicamycin DCONS86 Thioguanine Glioma (Cell Line: SF-268) [4]
Thioguanine + Plicamycin DCVGRT7 Thioguanine Glioma (Cell Line: SF-539) [4]
Thioguanine + Plicamycin DCHE0MO Thioguanine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Thioguanine + Plicamycin DCU0MML Thioguanine Renal cell carcinoma (Cell Line: SN12C) [4]
Thioguanine + Plicamycin DCLYTBH Thioguanine Renal cell carcinoma (Cell Line: UO-31) [4]
Thioguanine + Plicamycin DCRLIJ9 Thioguanine Invasive ductal carcinoma (Cell Line: BT-549) [5]
Thioguanine + Plicamycin DCH7VUS Thioguanine Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Thioguanine + Plicamycin DCSXTZE Thioguanine Adenocarcinoma (Cell Line: HCC-2998) [6]
Thioguanine + Plicamycin DCCVVD5 Thioguanine Adenocarcinoma (Cell Line: HCT116) [6]
Thioguanine + Plicamycin DCBBS3R Thioguanine Adenocarcinoma (Cell Line: SW-620) [6]
Thioguanine + Plicamycin DC18PVF Thioguanine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Thioguanine + Plicamycin DCLGJ22 Thioguanine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Thioguanine + Plicamycin DCM1C07 Thioguanine Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Thioguanine + Plicamycin DCX2ICZ Thioguanine Lung adenocarcinoma (Cell Line: HOP-62) [6]
Thioguanine + Plicamycin DC4US7Z Thioguanine Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Thioguanine + Plicamycin DCWAI88 Thioguanine Malignant melanoma (Cell Line: UACC62) [6]
Thioguanine + Plicamycin DCWMPLW Thioguanine Melanoma (Cell Line: MALME-3M) [6]
Thioguanine + Plicamycin DCN6AZO Thioguanine Melanoma (Cell Line: SK-MEL-2) [6]
Thioguanine + Plicamycin DCFR43N Thioguanine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Thioguanine + Plicamycin DCL2RVI Thioguanine Non-small cell lung carcinoma (Cell Line: HOP-92) [6]
Topotecan + Plicamycin DCBV4UX Topotecan Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Topotecan + Plicamycin DCXEPOI Topotecan Carcinoma (Cell Line: RXF 393) [5]
Topotecan + Plicamycin DCWPAP7 Topotecan Carcinoma (Cell Line: MCF7) [5]
Topotecan + Plicamycin DCJPO4J Topotecan Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Topotecan + Plicamycin DCKL2TE Topotecan Adenocarcinoma (Cell Line: A549) [6]
Topotecan + Plicamycin DCZFFS0 Topotecan Adenocarcinoma (Cell Line: SW-620) [6]
Topotecan + Plicamycin DCB69F5 Topotecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [6]
Topotecan + Plicamycin DC27LN9 Topotecan Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Topotecan + Plicamycin DCXTAFG Topotecan Clear cell renal cell carcinoma (Cell Line: 786-0) [6]
Topotecan + Plicamycin DCRMB17 Topotecan Clear cell renal cell carcinoma (Cell Line: TK-10) [6]
Topotecan + Plicamycin DC2P06D Topotecan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [6]
Topotecan + Plicamycin DCMP9R4 Topotecan Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Topotecan + Plicamycin DC6FXG1 Topotecan Glioblastoma (Cell Line: SNB-75) [6]
Topotecan + Plicamycin DC0TOI6 Topotecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Topotecan + Plicamycin DCOW38N Topotecan Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Topotecan + Plicamycin DCD8ZT7 Topotecan Melanoma (Cell Line: MALME-3M) [6]
Topotecan + Plicamycin DC72SEM Topotecan Melanoma (Cell Line: SK-MEL-2) [6]
Topotecan + Plicamycin DCEHBHL Topotecan Melanoma (Cell Line: UACC-257) [6]
Topotecan + Plicamycin DCJWGDK Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Topotecan + Plicamycin DCAAJDR Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Topotecan + Plicamycin DCUKVM3 Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Topotecan + Plicamycin DCVN2FV Topotecan Papillary renal cell carcinoma (Cell Line: ACHN) [6]
Topotecan + Plicamycin DCBXF00 Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Topotecan + Plicamycin DCEFZUE Topotecan Prostate carcinoma (Cell Line: PC-3) [6]
Triapine + Plicamycin DCFSTII Triapine Colon adenocarcinoma (Cell Line: COLO 205) [5]
Triapine + Plicamycin DCHGVTS Triapine Adenocarcinoma (Cell Line: A549) [6]
Triapine + Plicamycin DCMS7SF Triapine Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Triapine + Plicamycin DCGRKRJ Triapine Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Triapine + Plicamycin DCBW9UE Triapine Glioblastoma (Cell Line: SNB-75) [6]
Triapine + Plicamycin DCFQJ0R Triapine Glioma (Cell Line: SF-295) [6]
Triapine + Plicamycin DCD6281 Triapine Glioma (Cell Line: SF-539) [6]
Triapine + Plicamycin DC7EGTV Triapine Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Triapine + Plicamycin DC23E9L Triapine Malignant melanoma (Cell Line: LOX IMVI) [6]
Triapine + Plicamycin DC71BCQ Triapine Melanoma (Cell Line: MALME-3M) [6]
Trifluridine + Plicamycin DCS6CND Trifluridine Astrocytoma (Cell Line: SNB-19) [4]
Trifluridine + Plicamycin DCPKJZ0 Trifluridine Carcinoma (Cell Line: RXF 393) [5]
Trifluridine + Plicamycin DCWDGZ2 Trifluridine Invasive ductal carcinoma (Cell Line: BT-549) [5]
Trifluridine + Plicamycin DCR8NCW Trifluridine Adenocarcinoma (Cell Line: SW-620) [6]
Trifluridine + Plicamycin DCUGX7I Trifluridine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Trifluridine + Plicamycin DCMO0HP Trifluridine Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Uracil mustard + Plicamycin DCCL81S Uracil mustard Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Uracil mustard + Plicamycin DCY670S Uracil mustard Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Uracil mustard + Plicamycin DCIBA6X Uracil mustard Anaplastic large cell lymphoma (Cell Line: SR) [4]
Uracil mustard + Plicamycin DCG17VQ Uracil mustard Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Uracil mustard + Plicamycin DCI9L3V Uracil mustard Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Uracil mustard + Plicamycin DCASNPD Uracil mustard Carcinoma (Cell Line: RXF 393) [5]
Uracil mustard + Plicamycin DCYH7VL Uracil mustard Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Uracil mustard + Plicamycin DCVW42Y Uracil mustard Adenocarcinoma (Cell Line: HCC-2998) [6]
Uracil mustard + Plicamycin DCW3EXO Uracil mustard High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Uracil mustard + Plicamycin DCGRHM2 Uracil mustard Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Uracil mustard + Plicamycin DC6AP8P Uracil mustard Malignant melanoma (Cell Line: UACC62) [6]
Uracil mustard + Plicamycin DCP7GNH Uracil mustard Melanoma (Cell Line: UACC-257) [6]
Valrubicin + Plicamycin DCPB8OE Valrubicin Astrocytoma (Cell Line: U251) [4]
Valrubicin + Plicamycin DCSMY4W Valrubicin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Valrubicin + Plicamycin DCW1ARM Valrubicin Clear cell renal cell carcinoma (Cell Line: A498) [4]
Valrubicin + Plicamycin DCY1GF4 Valrubicin Glioma (Cell Line: SF-295) [4]
Valrubicin + Plicamycin DCS7F2R Valrubicin Renal cell carcinoma (Cell Line: UO-31) [4]
Valrubicin + Plicamycin DCCDS9D Valrubicin Colon adenocarcinoma (Cell Line: COLO 205) [5]
Valrubicin + Plicamycin DC1LPRA Valrubicin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Valrubicin + Plicamycin DCSTK81 Valrubicin Adenocarcinoma (Cell Line: A549) [6]
Valrubicin + Plicamycin DCGQPVA Valrubicin Adenocarcinoma (Cell Line: HCT116) [6]
Valrubicin + Plicamycin DCNDQIQ Valrubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Valrubicin + Plicamycin DC4I2CK Valrubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Valrubicin + Plicamycin DCN27KX Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Valrubicin + Plicamycin DC6OBD5 Valrubicin Lung adenocarcinoma (Cell Line: HOP-62) [6]
Valrubicin + Plicamycin DCXPKWA Valrubicin Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Valrubicin + Plicamycin DCQKAVO Valrubicin Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Valrubicin + Plicamycin DCQWWIG Valrubicin Malignant melanoma (Cell Line: UACC62) [6]
Valrubicin + Plicamycin DCR54V6 Valrubicin Melanoma (Cell Line: MALME-3M) [6]
Valrubicin + Plicamycin DCPRQX4 Valrubicin Melanoma (Cell Line: UACC-257) [6]
Valrubicin + Plicamycin DCQQIZB Valrubicin Melanoma (Cell Line: SK-MEL-2) [6]
Valrubicin + Plicamycin DCW04JH Valrubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Vandetanib + Plicamycin DCMXU67 Vandetanib Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Vandetanib + Plicamycin DC8EG5B Vandetanib Carcinoma (Cell Line: RXF 393) [5]
Vandetanib + Plicamycin DC4MX92 Vandetanib Carcinoma (Cell Line: MCF7) [5]
Vandetanib + Plicamycin DCFG64T Vandetanib Colon adenocarcinoma (Cell Line: COLO 205) [5]
Vandetanib + Plicamycin DC1ZUME Vandetanib Colon carcinoma (Cell Line: KM12) [5]
Vandetanib + Plicamycin DCXL1JX Vandetanib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Vandetanib + Plicamycin DCSVKD2 Vandetanib Invasive ductal carcinoma (Cell Line: BT-549) [5]
Vandetanib + Plicamycin DC075PN Vandetanib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Vandetanib + Plicamycin DC2KTUU Vandetanib Adenocarcinoma (Cell Line: OVCAR3) [6]
Vandetanib + Plicamycin DC1RR2M Vandetanib Adenocarcinoma (Cell Line: HCC-2998) [6]
Vandetanib + Plicamycin DC2MQOI Vandetanib Adenocarcinoma (Cell Line: SW-620) [6]
Vandetanib + Plicamycin DC0N9PP Vandetanib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [6]
Vandetanib + Plicamycin DCYRQMC Vandetanib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [6]
Vandetanib + Plicamycin DC4A7V8 Vandetanib Amelanotic melanoma (Cell Line: M14) [6]
Vandetanib + Plicamycin DCMGISY Vandetanib Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Vandetanib + Plicamycin DC4V16Y Vandetanib Anaplastic large cell lymphoma (Cell Line: SR) [6]
Vandetanib + Plicamycin DCRV7HJ Vandetanib Astrocytoma (Cell Line: U251) [6]
Vandetanib + Plicamycin DC16JX9 Vandetanib Astrocytoma (Cell Line: SNB-19) [6]
Vandetanib + Plicamycin DCTSJJX Vandetanib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [6]
Vandetanib + Plicamycin DCU3OPO Vandetanib Chronic myelogenous leukemia (Cell Line: K-562) [6]
Vandetanib + Plicamycin DCXJP64 Vandetanib Clear cell renal cell carcinoma (Cell Line: 786-0) [6]
Vandetanib + Plicamycin DCX5T9P Vandetanib Clear cell renal cell carcinoma (Cell Line: A498) [6]
Vandetanib + Plicamycin DC1CX8P Vandetanib Clear cell renal cell carcinoma (Cell Line: TK-10) [6]
Vandetanib + Plicamycin DCESLPW Vandetanib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [6]
Vandetanib + Plicamycin DC9749A Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Vandetanib + Plicamycin DCM0HO4 Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Vandetanib + Plicamycin DC5ITWK Vandetanib Glioblastoma (Cell Line: SNB-75) [6]
Vandetanib + Plicamycin DCMCFDA Vandetanib Glioma (Cell Line: SF-268) [6]
Vandetanib + Plicamycin DC7VTDP Vandetanib Glioma (Cell Line: SF-295) [6]
Vandetanib + Plicamycin DCL880I Vandetanib Glioma (Cell Line: SF-539) [6]
Vandetanib + Plicamycin DCWYWBU Vandetanib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Vandetanib + Plicamycin DCLGCPM Vandetanib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Vandetanib + Plicamycin DC3CCR0 Vandetanib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Vandetanib + Plicamycin DC8T1LI Vandetanib Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Vandetanib + Plicamycin DCMN2WW Vandetanib Malignant melanoma (Cell Line: UACC62) [6]
Vandetanib + Plicamycin DCYWALF Vandetanib Melanoma (Cell Line: MALME-3M) [6]
Vandetanib + Plicamycin DCPUVQO Vandetanib Melanoma (Cell Line: SK-MEL-2) [6]
Vandetanib + Plicamycin DCSJF9W Vandetanib Melanoma (Cell Line: UACC-257) [6]
Vandetanib + Plicamycin DCF0Q6H Vandetanib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Vandetanib + Plicamycin DCHXIWX Vandetanib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Vandetanib + Plicamycin DCIQWLL Vandetanib Papillary renal cell carcinoma (Cell Line: ACHN) [6]
Vandetanib + Plicamycin DCFBSJ0 Vandetanib Plasma cell myeloma (Cell Line: RPMI-8226) [6]
Vandetanib + Plicamycin DCAQR6T Vandetanib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Vandetanib + Plicamycin DCFH1B7 Vandetanib Renal cell carcinoma (Cell Line: UO-31) [6]
Vemurafenib + Plicamycin DC05WSL Vemurafenib Carcinoma (Cell Line: RXF 393) [5]
Vemurafenib + Plicamycin DCWHHQN Vemurafenib Carcinoma (Cell Line: MCF7) [5]
Vemurafenib + Plicamycin DCH9FDL Vemurafenib Colon adenocarcinoma (Cell Line: COLO 205) [5]
Vemurafenib + Plicamycin DCF9N8A Vemurafenib Colon carcinoma (Cell Line: KM12) [5]
Vemurafenib + Plicamycin DCX9W8B Vemurafenib Invasive ductal carcinoma (Cell Line: BT-549) [5]
Vemurafenib + Plicamycin DCNLBE5 Vemurafenib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Vemurafenib + Plicamycin DCZTZ9E Vemurafenib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Vemurafenib + Plicamycin DCKNOV8 Vemurafenib Adenocarcinoma (Cell Line: DU-145) [6]
Vemurafenib + Plicamycin DCWDJ7M Vemurafenib Adenocarcinoma (Cell Line: OVCAR3) [6]
Vemurafenib + Plicamycin DCX4V28 Vemurafenib Adenocarcinoma (Cell Line: NCIH23) [6]
Vemurafenib + Plicamycin DC38VHF Vemurafenib Adenocarcinoma (Cell Line: A549) [6]
Vemurafenib + Plicamycin DCNPD62 Vemurafenib Adenocarcinoma (Cell Line: HT29) [6]
Vemurafenib + Plicamycin DCQP8CV Vemurafenib Adenocarcinoma (Cell Line: HCT116) [6]
Vemurafenib + Plicamycin DC75NC1 Vemurafenib Adenocarcinoma (Cell Line: SW-620) [6]
Vemurafenib + Plicamycin DC4HP4E Vemurafenib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [6]
Vemurafenib + Plicamycin DC9IRHW Vemurafenib Amelanotic melanoma (Cell Line: M14) [6]
Vemurafenib + Plicamycin DCPX94P Vemurafenib Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Vemurafenib + Plicamycin DCPOKL4 Vemurafenib Anaplastic large cell lymphoma (Cell Line: SR) [6]
Vemurafenib + Plicamycin DC6J564 Vemurafenib Astrocytoma (Cell Line: SNB-19) [6]
Vemurafenib + Plicamycin DC4QSK0 Vemurafenib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [6]
Vemurafenib + Plicamycin DCXI08Y Vemurafenib Chronic myelogenous leukemia (Cell Line: K-562) [6]
Vemurafenib + Plicamycin DCYV3QO Vemurafenib Clear cell renal cell carcinoma (Cell Line: 786-0) [6]
Vemurafenib + Plicamycin DCA533J Vemurafenib Clear cell renal cell carcinoma (Cell Line: A498) [6]
Vemurafenib + Plicamycin DCCMNUO Vemurafenib Clear cell renal cell carcinoma (Cell Line: TK-10) [6]
Vemurafenib + Plicamycin DCNYD2H Vemurafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [6]
Vemurafenib + Plicamycin DCQT4Y1 Vemurafenib Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Vemurafenib + Plicamycin DCAP0KL Vemurafenib Glioblastoma (Cell Line: SNB-75) [6]
Vemurafenib + Plicamycin DCS7X3S Vemurafenib Glioma (Cell Line: SF-268) [6]
Vemurafenib + Plicamycin DC15OV4 Vemurafenib Glioma (Cell Line: SF-295) [6]
Vemurafenib + Plicamycin DC011S5 Vemurafenib Glioma (Cell Line: SF-539) [6]
Vemurafenib + Plicamycin DCQ1ZBC Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Vemurafenib + Plicamycin DCKFN6S Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Vemurafenib + Plicamycin DCCYIUS Vemurafenib Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Vemurafenib + Plicamycin DCSKY2I Vemurafenib Lung adenocarcinoma (Cell Line: HOP-62) [6]
Vemurafenib + Plicamycin DCQ8Z73 Vemurafenib Lung adenocarcinoma (Cell Line: EKVX) [6]
Vemurafenib + Plicamycin DCM0TGK Vemurafenib Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Vemurafenib + Plicamycin DC9WWA4 Vemurafenib Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Vemurafenib + Plicamycin DCQ0NHB Vemurafenib Malignant melanoma (Cell Line: LOX IMVI) [6]
Vemurafenib + Plicamycin DCS9CG3 Vemurafenib Malignant melanoma (Cell Line: UACC62) [6]
Vemurafenib + Plicamycin DCVQHZW Vemurafenib Melanoma (Cell Line: MALME-3M) [6]
Vemurafenib + Plicamycin DC82YZ1 Vemurafenib Melanoma (Cell Line: UACC-257) [6]
Vemurafenib + Plicamycin DCOO583 Vemurafenib Melanoma (Cell Line: SK-MEL-2) [6]
Vemurafenib + Plicamycin DCRAZRU Vemurafenib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Vemurafenib + Plicamycin DC1IN24 Vemurafenib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Vemurafenib + Plicamycin DCJAPNR Vemurafenib Non-small cell lung carcinoma (Cell Line: HOP-92) [6]
Vemurafenib + Plicamycin DCWG8IE Vemurafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Vemurafenib + Plicamycin DCT1WMY Vemurafenib Papillary renal cell carcinoma (Cell Line: ACHN) [6]
Vemurafenib + Plicamycin DCD3D9F Vemurafenib Plasma cell myeloma (Cell Line: RPMI-8226) [6]
Vemurafenib + Plicamycin DCSTHBE Vemurafenib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Vemurafenib + Plicamycin DCZEDLB Vemurafenib Prostate carcinoma (Cell Line: PC-3) [6]
Vemurafenib + Plicamycin DCSCYQT Vemurafenib Renal cell carcinoma (Cell Line: UO-31) [6]
Vemurafenib + Plicamycin DCFAJ2B Vemurafenib Renal cell carcinoma (Cell Line: SN12C) [6]
Vincristine + Plicamycin DCM71N1 Vincristine Adenocarcinoma (Cell Line: OVCAR3) [4]
Vincristine + Plicamycin DCVT1HB Vincristine Adenocarcinoma (Cell Line: NCIH23) [4]
Vincristine + Plicamycin DCDGWBY Vincristine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Vincristine + Plicamycin DC5B7NS Vincristine Hodgkin lymphoma (Cell Line: L-1236) [4]
Vincristine + Plicamycin DC9KQ2L Vincristine Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vinflunine + Plicamycin DCXMK0R Vinflunine Amelanotic melanoma (Cell Line: M14) [6]
Vinflunine + Plicamycin DCM5WVV Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Vismodegib + Plicamycin DCLEA4E Vismodegib Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Vismodegib + Plicamycin DCBKWNH Vismodegib Carcinoma (Cell Line: RXF 393) [5]
Vismodegib + Plicamycin DCGGB2G Vismodegib Carcinoma (Cell Line: MCF7) [5]
Vismodegib + Plicamycin DCB1RJN Vismodegib Colon adenocarcinoma (Cell Line: COLO 205) [5]
Vismodegib + Plicamycin DCIHIS4 Vismodegib Colon carcinoma (Cell Line: KM12) [5]
Vismodegib + Plicamycin DC7MKIN Vismodegib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Vismodegib + Plicamycin DC1JVD5 Vismodegib Invasive ductal carcinoma (Cell Line: BT-549) [5]
Vismodegib + Plicamycin DCMEQRO Vismodegib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Vismodegib + Plicamycin DCTXME4 Vismodegib Adenocarcinoma (Cell Line: DU-145) [6]
Vismodegib + Plicamycin DCG2MMK Vismodegib Adenocarcinoma (Cell Line: OVCAR3) [6]
Vismodegib + Plicamycin DCM5SO5 Vismodegib Adenocarcinoma (Cell Line: NCIH23) [6]
Vismodegib + Plicamycin DCVBNR2 Vismodegib Adenocarcinoma (Cell Line: A549) [6]
Vismodegib + Plicamycin DCX2KEU Vismodegib Adenocarcinoma (Cell Line: SW-620) [6]
Vismodegib + Plicamycin DCKN4FX Vismodegib Adenocarcinoma (Cell Line: HT29) [6]
Vismodegib + Plicamycin DCCUBBT Vismodegib Adenocarcinoma (Cell Line: HCT116) [6]
Vismodegib + Plicamycin DCQV22I Vismodegib Adenocarcinoma (Cell Line: HCC-2998) [6]
Vismodegib + Plicamycin DC1BDZS Vismodegib Adenocarcinoma (Cell Line: HCT-15) [6]
Vismodegib + Plicamycin DCPXMVW Vismodegib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [6]
Vismodegib + Plicamycin DCC6DIU Vismodegib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [6]
Vismodegib + Plicamycin DCCZ9ZH Vismodegib Amelanotic melanoma (Cell Line: M14) [6]
Vismodegib + Plicamycin DCGDOKI Vismodegib Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Vismodegib + Plicamycin DC7NMBP Vismodegib Anaplastic large cell lymphoma (Cell Line: SR) [6]
Vismodegib + Plicamycin DCRJWU1 Vismodegib Astrocytoma (Cell Line: U251) [6]
Vismodegib + Plicamycin DCW91Z3 Vismodegib Astrocytoma (Cell Line: SNB-19) [6]
Vismodegib + Plicamycin DCS9T4Y Vismodegib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [6]
Vismodegib + Plicamycin DCZQRX8 Vismodegib Chronic myelogenous leukemia (Cell Line: K-562) [6]
Vismodegib + Plicamycin DCKN4HV Vismodegib Clear cell renal cell carcinoma (Cell Line: TK-10) [6]
Vismodegib + Plicamycin DCCHRLV Vismodegib Clear cell renal cell carcinoma (Cell Line: 786-0) [6]
Vismodegib + Plicamycin DCHJ0BT Vismodegib Clear cell renal cell carcinoma (Cell Line: A498) [6]
Vismodegib + Plicamycin DC73YCW Vismodegib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [6]
Vismodegib + Plicamycin DCBCLMM Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Vismodegib + Plicamycin DC9TDZB Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Vismodegib + Plicamycin DCJWXRD Vismodegib Glioblastoma (Cell Line: SNB-75) [6]
Vismodegib + Plicamycin DCA2JMR Vismodegib Glioma (Cell Line: SF-539) [6]
Vismodegib + Plicamycin DCO0DKH Vismodegib Glioma (Cell Line: SF-268) [6]
Vismodegib + Plicamycin DCUO9ZK Vismodegib Glioma (Cell Line: SF-295) [6]
Vismodegib + Plicamycin DCQMY29 Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Vismodegib + Plicamycin DC4B6II Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Vismodegib + Plicamycin DCG83A6 Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Vismodegib + Plicamycin DCGOKUU Vismodegib Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Vismodegib + Plicamycin DC4KTV5 Vismodegib Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Vismodegib + Plicamycin DCY9RJ5 Vismodegib Lung adenocarcinoma (Cell Line: EKVX) [6]
Vismodegib + Plicamycin DCB4OVA Vismodegib Lung adenocarcinoma (Cell Line: HOP-62) [6]
Vismodegib + Plicamycin DCZQ6NC Vismodegib Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Vismodegib + Plicamycin DCSNYNM Vismodegib Malignant melanoma (Cell Line: UACC62) [6]
Vismodegib + Plicamycin DC5RVLC Vismodegib Malignant melanoma (Cell Line: LOX IMVI) [6]
Vismodegib + Plicamycin DCQZCEW Vismodegib Melanoma (Cell Line: SK-MEL-2) [6]
Vismodegib + Plicamycin DCFCDEV Vismodegib Melanoma (Cell Line: UACC-257) [6]
Vismodegib + Plicamycin DC7AS3H Vismodegib Melanoma (Cell Line: MALME-3M) [6]
Vismodegib + Plicamycin DC63WZ7 Vismodegib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Vismodegib + Plicamycin DC3NCKM Vismodegib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Vismodegib + Plicamycin DCWU77T Vismodegib Non-small cell lung carcinoma (Cell Line: HOP-92) [6]
Vismodegib + Plicamycin DCZ20C5 Vismodegib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Vismodegib + Plicamycin DCKX3NP Vismodegib Papillary renal cell carcinoma (Cell Line: ACHN) [6]
Vismodegib + Plicamycin DC0B4ID Vismodegib Plasma cell myeloma (Cell Line: RPMI-8226) [6]
Vismodegib + Plicamycin DCVJQT0 Vismodegib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Vismodegib + Plicamycin DCV43TU Vismodegib Prostate carcinoma (Cell Line: PC-3) [6]
Vismodegib + Plicamycin DCLRXZY Vismodegib Renal cell carcinoma (Cell Line: UO-31) [6]
Vismodegib + Plicamycin DCL41I9 Vismodegib Renal cell carcinoma (Cell Line: SN12C) [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 1370 DrugCom(s)

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8394).
3 The Pluripotency Factor Musashi-2 Is a Novel Target for Lung Cancer Therapy.Ann Am Thorac Soc. 2018 Apr;15(Supplement_2):S124.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
6 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.